[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1887
1. Ecklund EH, Cadge W, Gage EA, Catlin EA: The religious and spiritual beliefs and practices of academic pediatric oncologists in the United States. J Pediatr Hematol Oncol; 2007 Nov;29(11):736-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The religious and spiritual beliefs and practices of academic pediatric oncologists in the United States.
  • This study evaluates religious and spiritual beliefs and practices among pediatric oncology faculty and compares their religiosity and spirituality to the general public.
  • METHODS: Information was gathered from a sampling frame of all pediatric oncology faculty working in 13 US News and World Report's "honor role" hospitals.
  • RESULTS: Eighty-five percent of pediatric oncology faculty described themselves as spiritual.
  • Twenty-seven percent of pediatric oncologists believed in God with no doubts.
  • CONCLUSIONS: Although many have no traditional religious identity, large fractions of pediatric oncology faculty described themselves as spiritual.
  • This may have implications for the education of pediatric oncologists and the spiritual care of seriously ill children and their families.

  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Nov;29(11):733-5 [17984689.001]
  • (PMID = 17984690.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Holleman A, den Boer ML, Kazemier KM, Beverloo HB, von Bergh AR, Janka-Schaub GE, Pieters R: Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood; 2005 Sep 1;106(5):1817-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
  • Drug resistance in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with impaired ability to induce apoptosis.
  • To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).
  • In conclusion, low baseline expression of PARP and procaspase-2 is related to cellular drug resistance in childhood acute lymphoblastic leukemia.
  • [MeSH-major] Caspases / metabolism. Drug Resistance, Neoplasm / physiology. Poly(ADP-ribose) Polymerases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Apoptosis / physiology. Caspase 2. Cell Line, Tumor. Child. Drug Screening Assays, Antitumor. Gene Expression Regulation, Enzymologic. Humans. RNA, Messenger / genetics. RNA, Messenger / physiology


3. Choit RL, Jamieson DH, Reilly CW: Os odontoideum: a significant radiographic finding. Pediatr Radiol; 2005 Aug;35(8):803-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Os odontoideum can lead to instability of the atlantoaxial joint and places the spinal cord at significant risk for acute catastrophic events after minor trauma or chronic neurological change.
  • We present two cases of os odontoideum in pediatric patients that were not appreciated at earlier remote imaging but were, in retrospect, detectable.
  • One patient presented with an acute spinal cord injury.
  • Incorporating assessment of dens integrity into the evaluation algorithm for all pediatric cervical spine studies should lead to early detection of os odontoideum lesions and allow referral to appropriate clinical spinal services for evaluation, surveillance and possible surgery to prevent future complications.
  • [MeSH-minor] Adolescent. Atlanto-Axial Joint / diagnostic imaging. Atlanto-Axial Joint / pathology. Child. Diagnosis, Differential. Female. Humans. Joint Instability / diagnosis. Magnetic Resonance Imaging. Male. Radiography. Spinal Cord Injuries / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Orthop. 1990 Sep-Oct;10 (5):602-6 [2144298.001]
  • [Cites] J Bone Joint Surg Am. 1969 Jul;51(5):965-72 [5793853.001]
  • [Cites] J Bone Joint Surg Am. 1963 Oct;45:1459-71 [14069784.001]
  • [Cites] Spine (Phila Pa 1976). 2000 May 1;25(9):1178-81 [10788864.001]
  • [Cites] Ann Emerg Med. 1989 Dec;18(12 ):1358-61 [2589705.001]
  • [Cites] J Bone Joint Surg Am. 1974 Jan;56(1):187-90 [4812163.001]
  • [Cites] J Pediatr Orthop. 1998 Nov-Dec;18(6):815-9 [9821143.001]
  • [Cites] Acta Orthop Scand. 1983 Feb;54(1):113-8 [6829275.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1990 Aug;98 (2):89-93 [2378323.001]
  • [Cites] J Bone Joint Surg Am. 1976 Apr;58(3):413-4 [1262377.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1987 May;91(5):414-26 [3554978.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Nov 1;25(21):2777-83 [11064523.001]
  • [Cites] Eur Spine J. 2004 Jul;13(4):295-300 [15232724.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 2003 Aug;124(2):184-9 [12923515.001]
  • [Cites] J Bone Joint Surg Am. 1965 Oct;47(7):1295-309 [5837630.001]
  • [Cites] Am J Forensic Med Pathol. 1990 Sep;11(3):252-6 [2220713.001]
  • [Cites] Radiology. 1952 Nov;59(5):712-9 [12994006.001]
  • [Cites] J Bone Joint Surg Am. 1980 Apr;62(3):376-83 [7364809.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1999 Nov;116(5):572-7 [10547519.001]
  • [Cites] J Pediatr Orthop. 1991 Mar-Apr;11(2):222-5 [2010525.001]
  • [Cites] J Bone Joint Surg Am. 1991 Dec;73(10 ):1547-54 [1836215.001]
  • [Cites] Pediatr Radiol. 2002 Jan;32(1):34-40 [11819061.001]
  • (PMID = 15864578.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Yang YL, Lin DT, Chang SK, Lin SR, Lin SW, Chiou RJ, Yen CT, Lin KH, Jou ST, Lu MY, Chang HH, Chang WH, Lin KS, Hu CY: Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2010 Feb;54(2):206-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia.
  • OBJECTIVES: This retrospective study evaluates the role of pharmacogenomic determinants in the treatment of childhood acute lymphoblastic leukemia (ALL) in the Taiwanese population.
  • METHODS: A total of 105 childhood ALL patients received combined chemotherapy of different intensities based on risk-directed Taiwan Pediatric Oncology Group (TPOG)-ALL-93 protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Drug Resistance / genetics. P-Glycoprotein / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Asian Continental Ancestry Group / genetics. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Pharmacogenetics. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Taiwan


5. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG): Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol; 2009 May;145(3):376-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.
  • Anthracyclines are used to treat childhood acute lymphoblastic leukaemia (ALL) but non-randomized studies suggest that cardiotoxicity may be a problem.
  • Individual patient data from trials in childhood ALL that randomized anthracyclines or methods of reducing cardiotoxicity were analysed by standard meta-analysis methods.
  • Results were grouped and combined according to: addition of an anthracycline to standard therapy, type of anthracycline, mode of administration, and the use of a cardioprotectant.
  • Anthracyclines are effective against bone marrow relapse but have not been shown to significantly increase event free survival in childhood ALL.
  • The evidence on type of anthracycline, method of administration or use of cardioprotectant was insufficient to be able to rule out important differences.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cardiotonic Agents / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Heart Diseases / chemically induced. Humans. Infant. Male. Odds Ratio. Randomized Controlled Trials as Topic. Remission Induction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14 [16781284.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3 Suppl 8):S2-7 [16781283.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005008 [17054232.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3191-8 [16987655.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):226-30 [17242696.001]
  • [Cites] Klin Padiatr. 2007 May-Jun;219(3):134-8 [17525906.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1444-54 [11230490.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):25-36 [11815957.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):503-12 [12056699.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1767-72 [12365026.001]
  • [Cites] Am J Hematol. 2002 Dec;71(4):241-7 [12447951.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] Cancer. 1974 Feb;33(2):545-54 [4521474.001]
  • [Cites] Ned Tijdschr Geneeskd. 1975 Sep 20;119(38):1445-51 [1101081.001]
  • [Cites] Cancer. 1976 Mar;37(3):1243-7 [1063049.001]
  • [Cites] Med Pediatr Oncol. 1977;3(3):281-7 [284168.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Summer;11(2):125-33 [2665546.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):187-96 [2064956.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3120-30 [8221579.001]
  • [Cites] Mol Aspects Med. 1994;15 Suppl:s207-12 [7752832.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(1):CD003917 [15674919.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005006 [17054231.001]
  • (PMID = 19236609.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / U10 CA029139-22; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Cardiotonic Agents
  • [Number-of-references] 29
  • [Other-IDs] NLM/ NIHMS163765; NLM/ PMC2812732
  • [Investigator] Yetgin S; Obek NY; Masera G; Valsecchi MG; Dacou-Voutetakis; Loening L; Schrappe M; Zimmermann M; Henze G; von Stackelberg A; Gadner H; Mann G; Attarbaschi A; Brandalise SR; Carroll WL; Gaynon P; Boyett JM; Nachman J; Devidas M; Sather HN; Escherich G; Janka G; Gelber RD; Sallan SE; Pieters R; Bierings M; Kamps WA; Otten J; Suciu S; Viana MB; Baruchel A; Auclerc M; Perez C; Solidaro A; Stark B; Steinberg D; Koizumi S; Tsurusawa M; Zintl F; Schiller I; Matsuzaki A; Eden TO; Lilleyman JS; Richards S; Steinherz PG; Steinherz L; Kochupillai V; Bakhshi S; Ortega JJ; Nachman J; Appelbaum FR; Cheng C; Pei D; Pui CH; Kukure P; Nakazawa S; Tsuchida M; Elphinstone T; Evans V; Gettins L; Hicks C; MacKinnon L; Morris P; Richards S; Wade R
  •  go-up   go-down


6. Khalid S, Moiz B, Adil SN, Khurshid M: Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):704-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience.
  • OBJECTIVE: We reviewed the clinical details and treatment outcome of children with newly diagnosed acute lymphoblastic leukemia (ALL) to determine the significance of already established prognostic factors in our patients.
  • CONCLUSION: We found that ALL is a frequent childhood hematological malignancy in our setting and is more prevalent in males and children less than ten years of age.
  • Age and leukemia phenotype emerged as the important prognostic factors in pediatric ALL in our patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Male. Pakistan / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Sex Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045397.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


7. Ariffin H, Chen SP, Kwok CS, Quah TC, Lin HP, Yeoh AE: Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia: results of the Malaysia-Singapore Leukemia Study Group. J Pediatr Hematol Oncol; 2007 Jan;29(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia: results of the Malaysia-Singapore Leukemia Study Group.
  • Childhood acute lymphoblastic leukemia (ALL) is clinically heterogeneous with prognostically and biologically distinct subtypes.
  • Although racial differences in frequency of different types of childhood ALL have been reported, many are confounded by selected or limited population samples.
  • The Malaysia-Singapore (MA-SPORE) Leukemia Study Group provided a unique platform for the study of the frequency of major subgroups of childhood ALL in a large cohort of unselected multiethnic Asian children.
  • Screening for the prognostically important chromosome abnormalities (TEL-AML1, BCR-ABL, E2A-PBX1, and MLL) using multiplex reverse-transcription polymerase chain reaction was performed on 299 consecutive patients with ALL at 3 study centers (236 de novo, 63 at relapse), with the ethnic composition predominantly Chinese (51.8%) and Malay (34.8%).
  • Chinese have a significantly lower frequency of TEL-AML1 (13.3% in de novo patients) compared with Malays (22.2%) and Indians (21.7%) (P=0.04).
  • Our study suggests that there are indeed significant and important racial differences in the frequency of subtypes of childhood ALL.
  • Comprehensive subgrouping of childhood ALL may reveal interesting population frequency differences of the various subtypes, their risk factors and hopefully, its etiology.
  • [MeSH-major] Asian Continental Ancestry Group. Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Malaysia. Male. Neoplasm Proteins / genetics. Prognosis. Risk Factors. Singapore

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Aug;29(8):585 [17762503.001]
  • (PMID = 17230064.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


8. Mkrtchyan H, Garcia Ney DR, de Ventura ES, Liehr T, Felix GR, Marques-Salles Tde J, Abdelhay E, Macedo Silva ML: Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 Feb;197(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia.
  • High hyperdiploidy with modal chromosome numbers between 50 and 65 is common in childhood acute lymphoblastic leukemia (ALL), occurring in 25-30% of the cases.
  • By contrast, near triploidy and tetraploidy are found in <1% of childhood ALL.
  • Here, we describe clinical and molecular cytogenetic findings in a child with ALL who had a near-triploid complex karyotype, with loss and gain of chromosomes, including extra copies of the same derivative chromosomes.
  • [MeSH-major] Chromosome Aberrations. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Female. Humans. Karyotyping

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20113840.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ: Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol; 2010 May;11(5):429-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.
  • BACKGROUND: Chromosomal abnormalities in childhood acute lymphoblastic leukaemia are well established disease markers and indicators of outcomes.
  • METHODS: We analysed cytogenetic data from 1725 children with B-cell precursor acute lymphoblastic leukaemia who were included in the UK Medical Research Council ALL97/99 study and followed up for a median time of 8.2 years.
  • FUNDING: Leukaemia and Lymphoma Research (LLR).
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Prognosis. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 May;11(5):403-4 [20409755.001]
  • [ErratumIn] Lancet Oncol. 2010 Jun;11(6):516
  • (PMID = 20409752.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Papadia C, Naves LA, Costa SS, Vaz JA, Domingues L, Casulari LA: Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1. Horm Res; 2007;68(4):164-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1.
  • BACKGROUND/AIMS: It has been reported that children treated for acute lymphoblastic leukemia (ALL) in developed countries show an increased risk of overweight and obesity in adolescence and adulthood.
  • METHODS: Two groups of subjects were studied: 27 survivors of childhood ALL (14.0 +/- 4.2 years old; post-treatment interval 8.6 +/- 3.9 years) (ALL group) and 17 healthy subjects (12.8 +/- 4 years old) (control group) selected on the basis of their kinship with the patients.
  • CONCLUSION: The data indicate the presence of alterations in the homeostatic regulatory mechanisms controlling body weight in Brazilian patients treated for ALL in childhood, still, it did not lead to obesity in the absence of favorable environmental conditions.
  • [MeSH-major] Insulin / physiology. Insulin-Like Growth Factor I / physiology. Leptin / physiology. Obesity / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Body Mass Index. Brazil. Child. Female. Follow-Up Studies. Humans. Incidence. Male. Waist-Hip Ratio


11. Tham EH, Tay SK, Low PS: Factors predictive of outcome in childhood stroke in an Asian population. Ann Acad Med Singapore; 2009 Oct;38(10):876-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predictive of outcome in childhood stroke in an Asian population.
  • The aim of this study was to evaluate the epidemiology of childhood stroke in a tertiary paediatric unit in Singapore and to assess factors influencing outcome in these children.
  • MATERIALS AND METHODS: A retrospective case-note review of all childhood strokes presenting to the Children's Medical Institute (CMI) at the National University Hospital (NUH), Singapore between October 1999 and May 2006.
  • [MeSH-minor] Adolescent. Age Factors. Asian Continental Ancestry Group. Brain Ischemia / epidemiology. Brain Ischemia / etiology. Brain Ischemia / rehabilitation. Cerebral Hemorrhage / etiology. Child. Child, Preschool. Developmental Disabilities / etiology. Female. Humans. Infant. Intracranial Arteriovenous Malformations / complications. Length of Stay / statistics & numerical data. Male. Neuropsychological Tests. Prognosis. Retrospective Studies. Risk Assessment. Risk Factors. Singapore / epidemiology. Treatment Outcome. Vascular Diseases / complications

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890579.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


12. Jain N, Brouwers P, Okcu MF, Cirino PT, Krull KR: Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia. Cancer; 2009 Sep 15;115(18):4238-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Neurocognitive problems are a frequent outcome of chemotherapy for pediatric leukemia, although individual differences exist in patient outcome.
  • The purpose of this study was to evaluate the pattern of attention problems in male and female long-term survivors of pediatric acute lymphoblastic leukemia (ALL).
  • CONCLUSIONS: The results of this study suggest that children diagnosed with and treated for pediatric ALL perform poorly on select measures of attention and executive control, and that this performance is influenced by sex and treatment intensity.
  • [MeSH-major] Attention. Cognition Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Sex Characteristics. Survivors / psychology
  • [MeSH-minor] Age of Onset. Child. Female. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19536898.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Hernández Sánchez JE, Gómez Vegas A, Blázquez Izquierdo J, Grimalt Alvarez J, Pérez Contín MJ, Rabadán Marina M, San José Manso L, Alonso Prieto M, Pérez Romero N, Silmi Moyano A: [En bloc transplantation of pediatric donor kidneys to adult receptors]. Arch Esp Urol; 2007 Mar;60(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [En bloc transplantation of pediatric donor kidneys to adult receptors].
  • [Transliterated title] Trasplante en bloque de riñones procedentes de donantes pediatricos en receptores adultos.
  • OBJECTIVES: Analysis of all pediatric donor en bloc transplants to adult receptors performed in our department.
  • RESULTS: There were significant differences in terms of nonfunctioning kidneys and delayed graft function, more frequent in pediatric en bloc and adult transplants, respectively.
  • Pediatric kidneys provided better renal function and less proteinuria.
  • One and five-year graft survivals were 83.56% and 8 1.47% for pediatric donor kidneys, and 91.50% and 86.99% for adult donor kidneys.
  • CONCLUSIONS: Pediatric donor en bloc transplants have an excellent survival and function in the middle and long-term.
  • Vascular complications are the main cause of pediatric donor graft loss.
  • The adoption of a pediatric donor en bloc transplant program increases the transplant activity.
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Female. Graft Survival. Humans. Immunosuppressive Agents / therapeutic use. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Spain. Survival Analysis. Tissue Donors. Tissue and Organ Procurement. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484481.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


14. Kamiya H, Nakano T, Inoue M, Kamiya H, Abd TT, Patel M, Orenstein WA, Parashar UD: A retrospective evaluation of hospitalizations for acute gastroenteritis at 2 sentinel hospitals in central Japan to estimate the health burden of rotavirus. J Infect Dis; 2009 Nov 1;200 Suppl 1:S140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective evaluation of hospitalizations for acute gastroenteritis at 2 sentinel hospitals in central Japan to estimate the health burden of rotavirus.
  • METHODS: To describe the epidemiology of severe rotavirus disease among Japanese children aged <5 years, we examined retrospective demographic, clinical, and laboratory data from the period 2003-2007 for children hospitalized with acute gastroenteritis (AGE) at 2 sentinel hospitals in Japan.
  • RESULTS: At each of the 2 hospitals, 17%-21% of all pediatric hospitalizations were for AGE.
  • [MeSH-minor] Acute Disease. Humans. Japan / epidemiology. Retrospective Studies. Seasons

  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • MedlinePlus Health Information. consumer health - Rotavirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817592.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Yanke BV, Horowitz M: Safety of the Veress needle in pediatric laparoscopy. J Endourol; 2007 Jul;21(7):695-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of the Veress needle in pediatric laparoscopy.
  • PURPOSE: To better establish the complication rate with the Veress needle technique for establishing a pneumoperitoneum in pediatric laparoscopy.
  • PATIENTS AND METHODS: We reviewed all pediatric laparoscopy cases performed by a single surgeon from 1996 to 2003.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705752.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Vijayakrishnan J, Houlston RS: Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica; 2010 Aug;95(8):1405-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
  • To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996-July 2009).
  • We identified 47 studies of polymorphic variation in 16 genes and acute lymphoblastic leukemia risk.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Genome-Wide Association Study / methods. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Humans. Odds Ratio. PubMed. Risk Factors


17. Marwaha RK, Kulkarni KP, Bansal D, Trehan A: Pattern of mortality in childhood acute lymphoblastic leukemia: experience from a single center in northern India. J Pediatr Hematol Oncol; 2010 Jul;32(5):366-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of mortality in childhood acute lymphoblastic leukemia: experience from a single center in northern India.
  • The outcome of acute lymphoblastic leukemia (ALL) in developing countries is inferior compared with the resource-rich nations.
  • [MeSH-major] Mortality / trends. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. India / epidemiology. Male. Radiotherapy Dosage. Retrospective Studies. Survival Rate


18. Cheng Q, Evans WE: Cancer pharmacogenomics may require both qualitative and quantitative approaches. Cell Cycle; 2005 Nov;4(11):1506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant advances have been achieved in event-free survival of patients with many types of cancer (most dramatically childhood acute lymphoblastic leukemia, ALL) through a better understanding of the pathobiology of human cancers, the cellular mechanisms of cancer chemotherapy, and the determinants of inter-individual differences in drug effects and treatment response.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258271.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 53
  •  go-up   go-down


19. Stanulla M, Schünemann HJ: Thioguanine versus mercaptopurine in childhood ALL. Lancet; 2006 Oct 14;368(9544):1304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thioguanine versus mercaptopurine in childhood ALL.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / therapeutic use
  • [MeSH-minor] Child. Disease-Free Survival. Humans. Randomized Controlled Trials as Topic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2006 Oct 14;368(9544):1339-48 [17046466.001]
  • (PMID = 17046444.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


20. Adelman AS, Groves FD, O'Rourke K, Sinha D, Hulsey TC, Lawson AB, Wartenberg D, Hoel DG: Residential mobility and risk of childhood acute lymphoblastic leukaemia: an ecological study. Br J Cancer; 2007 Jul 2;97(1):140-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential mobility and risk of childhood acute lymphoblastic leukaemia: an ecological study.
  • We conducted an ecological analysis of childhood acute lymphoblastic leukaemia-incidence data from children <or=5 years old during 1992-1998 from the Surveillance, Epidemiology, and End Results Program in 200 counties and Hawaii.
  • [MeSH-major] Population Dynamics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Child, Preschool. Female. Hawaii. Humans. Incidence. Income. Male. Poverty. Risk Factors. Sex Characteristics. United States. Urban Population

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):526-31 [15951671.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1057-64 [15184264.001]
  • [Cites] J Natl Cancer Inst. 1971 Sep;47(3):501-9 [5157573.001]
  • [Cites] Med J Aust. 1980 Aug 9;2(3):154-5 [6932561.001]
  • [Cites] J Epidemiol Community Health. 1981 Dec;35(4):245-50 [7338698.001]
  • [Cites] Br J Cancer. 1982 Oct;46(4):640-5 [6958309.001]
  • [Cites] Epidemiol Rev. 1985;7:22-48 [3902495.001]
  • [Cites] Pediatrie. 1988;43(1):59-65 [3387182.001]
  • [Cites] Int J Cancer. 1988 Oct 15;42(4):511-20 [3170025.001]
  • [Cites] Lancet. 1989 Nov 11;2(8672):1145-7 [2572858.001]
  • [Cites] J Public Health Med. 1990;12(2):109-17 [2223195.001]
  • [Cites] Lancet. 1990 Dec 15;336(8729):1461-5 [1979091.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):549-54 [1911197.001]
  • [Cites] Am J Epidemiol. 1992 Oct 15;136(8):916-24 [1456268.001]
  • [Cites] Acta Haematol. 1992;88(2-3):58-60 [1466202.001]
  • [Cites] J Public Health Med. 1993 Mar;15(1):9-15 [8471307.001]
  • [Cites] BMJ. 1993 Mar 20;306(6880):743-8 [8490337.001]
  • [Cites] BMJ. 1995 Mar 25;310(6982):763-8 [7711579.001]
  • [Cites] Cancer Causes Control. 1995 Sep;6(5):383-8 [8547535.001]
  • [Cites] Paediatr Perinat Epidemiol. 1996 Oct;10(4):411-7 [8931055.001]
  • [Cites] BMJ. 1996 Nov 23;313(7068):1297-300 [8942689.001]
  • [Cites] Br J Cancer. 1997;75(3):457-63 [9020498.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):239-45 [9134248.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):842-9 [9514068.001]
  • [Cites] Cancer Causes Control. 1998 May;9(3):285-98 [9684709.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):587-91 [9758111.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):30-3 [10408689.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):144-51 [10487626.001]
  • [Cites] Cancer. 1959 Mar-Apr;12(2):351-8 [13638954.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2084-8 [15886703.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):483-90 [11519756.001]
  • (PMID = 17533404.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359674
  •  go-up   go-down


21. Jeha S: New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):76-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic strategies in acute lymphoblastic leukemia.
  • While cure rates of over 80% are achieved in contemporary pediatric acute lymphoblastic leukemia (ALL) protocols, most adults with ALL succumb to their disease, and little progress has been made in the treatment of refractory and relapsed ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Drug Delivery Systems. Folic Acid / metabolism. Humans. Nucleosides / therapeutic use. Protein Kinase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100370.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Nucleosides; 0 / Protein Kinase Inhibitors; 935E97BOY8 / Folic Acid
  • [Number-of-references] 167
  •  go-up   go-down


22. Li F, Fridley BL, Matimba A, Kalari KR, Pelleymounter L, Moon I, Ji Y, Jenkins GD, Batzler A, Wang L, Weinshilboum RM: Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos; 2010 Dec;38(12):2329-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood.

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859351 for PMID:20855458 [PharmGKB] .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pflugers Arch. 2004 Feb;447(5):735-43 [12838422.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):259-66 [19732725.001]
  • [Cites] Biochemistry. 1969 Jan;8(1):122-30 [4304985.001]
  • [Cites] Biochem Pharmacol. 1969 Apr;18(4):936-8 [5788533.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] Br J Clin Pharmacol. 1983 Oct;16(4):359-63 [6578834.001]
  • [Cites] Clin Pharmacol Ther. 1987 Jan;41(1):18-25 [3467886.001]
  • [Cites] Lancet. 1987 Dec 19;2(8573):1471 [2892037.001]
  • [Cites] J Chromatogr. 1987 Dec 25;423:169-78 [3443647.001]
  • [Cites] Biomed Chromatogr. 1990 Mar;4(2):47-51 [2350596.001]
  • [Cites] J Biol Chem. 1990 Dec 25;265(36):22210-6 [2266122.001]
  • [Cites] J Chromatogr. 1991 Nov 15;571(1-2):149-56 [1810943.001]
  • [Cites] Biochem J. 1992 Jul 15;285 ( Pt 2):345-65 [1637327.001]
  • [Cites] Eur J Clin Pharmacol. 1992;43(4):329-39 [1451710.001]
  • [Cites] J Chromatogr. 1992 Nov 27;583(1):83-90 [1484095.001]
  • [Cites] Mol Pharmacol. 1993 Jun;43(6):878-87 [8316220.001]
  • [Cites] DNA Cell Biol. 1996 Jan;15(1):17-30 [8561894.001]
  • [Cites] Clin Chem. 1998 Dec;44(12):2511-5 [9836719.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1048-51 [10470083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9394-9 [15967990.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1778-85 [15905191.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1629-38 [16550163.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15 [16530731.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:223-45 [16948615.001]
  • [Cites] Am J Hum Genet. 1996 Apr;58(4):694-702 [8644731.001]
  • [Cites] Clin Chem. 1998 Mar;44(3):551-5 [9510860.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1998 Sep 25;716(1-2):392-6 [9824258.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8375-81 [10722669.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5810-6 [11479220.001]
  • [Cites] Mol Pharmacol. 2002 Dec;62(6):1321-31 [12435799.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Aug 15;18(4):395-400 [12940924.001]
  • [Cites] Pharmacogenetics. 2003 Sep;13(9):555-64 [12972954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63 [17537913.001]
  • [Cites] Leuk Res. 2008 May;32(5):799-809 [17996297.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3161-8 [18451141.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):4983-9 [18593894.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7050-8 [18757419.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):728-34 [12856181.001]
  • (PMID = 20855458.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM028157; United States / NCI NIH HHS / CA / R01-CA132780; United States / NIGMS NIH HHS / GM / R01-GM28157; United States / NIGMS NIH HHS / GM / U01 GM061388; United States / NCI NIH HHS / CA / R01 CA132780; United States / NCI NIH HHS / CA / K22 CA130828; United States / NIGMS NIH HHS / GM / GM061388-10; United States / NCI NIH HHS / CA / K22-CA130828; United States / NCI NIH HHS / CA / R01 CA132780-04; United States / NIGMS NIH HHS / GM / R01 GM028157-30; United States / NIGMS NIH HHS / GM / U01 GM061388-10; United States / NIGMS NIH HHS / GM / U01-GM61388; United States / NCI NIH HHS / CA / R01 CA138461; United States / NCI NIH HHS / CA / R01-CA138461
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCC4 protein, human; 0 / Multidrug Resistance-Associated Proteins; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase; EC 3.1.3.5 / 5'-Nucleotidase; FTK8U1GZNX / Thioguanine
  • [Other-IDs] NLM/ PMC2993460
  •  go-up   go-down


23. Bechtold S, Putzker S, Birnbaum J, Schwarz HP, Netz H, Dalla Pozza R: Impaired bone geometry after heart and heart-lung transplantation in childhood. Transplantation; 2010 Nov 15;90(9):1006-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired bone geometry after heart and heart-lung transplantation in childhood.
  • BACKGROUND: Impaired bone health has been advocated after solid organ transplantation in adult and pediatric patients.
  • CONCLUSION: After heart transplantation and heart-lung transplantation in childhood, all our patients showed altered bone geometry and low muscle CSA.
  • [MeSH-minor] Adolescent. Adult. Body Mass Index. Child. Diaphyses / anatomy & histology. Female. Forearm. Glucocorticoids / therapeutic use. Humans. Infant. Male. Radius / anatomy & histology


24. van Scherpenzeel Thim V, Remacle S, Picard J, Cornu G, Gofflot F, Rezsohazy R, Verellen-Dumoulin C: Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. Hum Mutat; 2005 Apr;25(4):384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function.
  • The molecular basis of susceptibility to childhood malignant hemopathy remains largely unknown.
  • We aimed to explore the possibility that germline alterations of HOX genes might be involved in childhood acute lymphoid malignancies.
  • A cohort of 86 children diagnosed with acute lymphoid malignancy was studied, 20 of them concurrently presenting a congenital anomaly of the skeleton.
  • While 13 changes were also observed in healthy controls, three variants were exclusively found in acute lymphoid malignancy cases.
  • These comprised the germline c.242A>T (p.Glu81Val) missense mutation of HOXD4, detected in two children diagnosed with acute lymphoblastic leukemia (ALL).
  • Functional analysis of the murine Hoxd4 homolog revealed that mutant Hoxd4 protein had lower transcriptional activity than wild-type protein in vitro.
  • The p.Glu81Val mutation of HOXD4 thus results in a partial loss-of-function, which might be involved in childhood ALL.
  • [MeSH-major] Germ-Line Mutation. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Animals. Child. Child, Preschool. Cohort Studies. DNA Mutational Analysis. Female. Haplotypes. Humans. Infant. Male. Mice. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776434.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 142981; RefSeq/ NM/ 014621
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXD1 protein, human; 0 / Homeodomain Proteins; 0 / Hoxd4 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


25. Xu XJ, Tang YM, Song H, Shi SW, Yang SL, Shen HQ, Wei J, Xu WQ, Pan BH, Zhao FY: [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance]. Zhonghua Er Ke Za Zhi; 2010 Mar;48(3):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
  • OBJECTIVE: Monitoring of minimal residual disease (MRD) is proven to be increasingly valuable for predicting relapse and outcome of childhood acute lymphoblastic leukemia (ALL) and is used to identify patients' risk groups in several current clinical trials.
  • The aim of this study was to investigate the predictive values of different MRD levels detected at different chemotherapy phases in childhood ALL.
  • All the patients were treated with modified National Protocol of Childhood ALL in China 1997.
  • All samples were stained with a panel of four colour combinations of fluorochrome conjugated monoclonal antibodies according to the leukemia-associated immunophenotype (LAIP) defined at diagnosis and analyzed by multi-parametric flow cytometry.
  • CONCLUSION: Dynamic MRD detection by multi-parametric flow cytometry is highly predictive of outcome for childhood ALL, and the cut-off values at different time points were different.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Infant, Newborn. Male. Neoplasm, Residual. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426951.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


26. Tofil NM, Lee White M, Manzella B, McGill D, Zinkan L: Initiation of a pediatric mock code program at a children's hospital. Med Teach; 2009 Jun;31(6):e241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initiation of a pediatric mock code program at a children's hospital.
  • BACKGROUND: Pediatric cardiopulmonary arrests are rare.
  • AIM: The goal was to improve medical caregivers' skills in pediatric resuscitation.
  • METHODS: All pediatric and internal medicine/pediatric (med/peds) residents were anonymously surveyed pre- and post-intervention about confidence level about codes and code skills.
  • Statistical comparisons were made between each resident pre- and post-survey, graduating third-year residents (PGY3s) prior to intervention versus PGY3s with mock codes and pediatric versus med/peds residents.
  • Med/peds residents were significantly more confident in their skills than pediatric residents both pre- (p = 0.041) and post-intervention (p = 0.016).
  • CONCLUSIONS: Pediatric mock codes can improve resident confidence and self-assessment of their resuscitation skills.
  • [MeSH-minor] Adult. Child. Child, Preschool. Data Collection. Educational Status. Female. Hospitals, Pediatric. Humans. Infant. Infant, Newborn. Internal Medicine / education. Male. Models, Educational. Patient Care Team. Pediatrics / education. Self-Assessment

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - CPR.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811155.001).
  • [ISSN] 1466-187X
  • [Journal-full-title] Medical teacher
  • [ISO-abbreviation] Med Teach
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Mahle WT: Cardiac retransplantation in children. Pediatr Transplant; 2008 May;12(3):274-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To discuss the indications for and outcomes of cardiac retransplantation in childhood.
  • The major challenge of pediatric heart transplantation is graft failure.
  • Retransplantation may be considered in children or young adults who develop graft failure following pediatric heart transplantation.
  • Retransplantation now accounts for 7% of all pediatric transplants.
  • Novel therapies to extend the life of the primary graft and to stratify those at risk of severe graft dysfunction will improve the allocation of scarce organs for pediatric patients who might be candidates for cardiac retransplantation.
  • [MeSH-minor] Child. Heart Diseases / complications. Heart Diseases / therapy. Humans. Immunosuppressive Agents / therapeutic use. Kidney Diseases / complications. Prognosis. Reoperation / methods. Reoperation / statistics & numerical data. Risk. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18435605.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


28. Leung W, Neale G, Behm F, Iyengar R, Finkelstein D, Kastan MB, Pui CH: Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol; 2010 Jun;34(3):303-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are at an increased risk of developing secondary malignant neoplasms.
  • In contrast, patients had lower numbers of all lymphocyte subsets involved in innate immunity (gammadeltaT cells and all NK subsets, including KIR2DL1+ cells, KIR2DL2/L3+ cells, and CD16+ cells), and lower natural cytotoxicity against K562 leukemia cells.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2000 Jan 1;95(1):352-9 [10607724.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):41-9 [11905813.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1036-42 [10973325.001]
  • [Cites] Lancet. 2000 Nov 25;356(9244):1795-9 [11117911.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] Nat Immunol. 2002 Jan;3(1):83-90 [11743585.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):224-7 [7913156.001]
  • [Cites] JAMA. 1994 Nov 9;272(18):1427-32 [7933424.001]
  • [Cites] Nature. 1995 May 11;375(6527):155-8 [7753173.001]
  • [Cites] Biochemistry. 1996 Jun 18;35(24):8035-44 [8672508.001]
  • [Cites] Blood. 2002 May 15;99(10):3661-7 [11986221.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Genome Res. 2004 Feb;14(2):287-95 [14762065.001]
  • [Cites] Genome Res. 2004 Mar;14(3):414-25 [14993208.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4464-71 [15231655.001]
  • [Cites] Blood. 1972 Jul;40(1):42-51 [4624721.001]
  • [Cites] Cancer Res. 1982 Oct;42(10):4289-92 [6955009.001]
  • [Cites] Med Pediatr Oncol. 1986;14(6):295-9 [3466000.001]
  • [Cites] Lancet. 1987 Jan 24;1(8526):190-3 [2880018.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):136-42 [2787477.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):143-51 [2501681.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Biomed Pharmacother. 1996;50(3-4):125-31 [8881368.001]
  • [Cites] Immunol Rev. 1997 Dec;160:159-70 [9476674.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Mutat Res. 1998 Dec 3;422(2):213-22 [9838123.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):316-23 [15549093.001]
  • [Cites] Cell. 2005 Feb 25;120(4):497-512 [15734682.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6540-5 [15879158.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1749-54 [15920008.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Curr Opin Immunol. 2006 Feb;18(1):31-8 [16337364.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):261-70 [16498454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10672-7 [16807291.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):344-7 [16914325.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):915-21 [16877676.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1717-22 [16888619.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):85-92 [18084281.001]
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • (PMID = 20413363.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-24; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / P30 CA-21765-24
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS193817; NLM/ PMC2874127
  •  go-up   go-down


29. Ge Y, Haska CL, LaFiura K, Devidas M, Linda SB, Liu M, Thomas R, Taub JW, Matherly LH: Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clin Cancer Res; 2007 Jan 15;13(2 Pt 1):451-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  • PURPOSE: The value of measuring expression of individual genes relevant to particular chemotherapy drugs and encoding metabolizing enzymes, transporters, or drug targets, as predictors of treatment response and outcome in pediatric acute lymphoblastic leukemia (ALL), remains controversial.
  • EXPERIMENTAL DESIGN: In a case-control population of 91 pediatric B-precursor ALL patients [42 relapsed within 4 years (cases) and 49 did not relapse (controls)], we used real-time reverse transcription-PCR to measure transcript levels for 20 genes relevant to chemotherapy with the five major drugs used to treat this disease, including asparaginase, 6-mercaptopurine, methotrexate, prednisone, and vincristine.
  • CONCLUSIONS: Our results strongly suggest the prognostic importance of hRFC gene expression to treatment outcomes in pediatric ALL.
  • They validate our previous studies of hRFC transcriptional regulation in pediatric ALL and provide further compelling evidence for the critical role for methotrexate in the successful treatment of this disease.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Gene Expression Regulation, Neoplastic. Membrane Transport Proteins / physiology. Methotrexate / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Biological Transport. Case-Control Studies. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Male. Prognosis. RNA, Messenger / metabolism. Recurrence. Reduced Folate Carrier Protein. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255265.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 76641
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


30. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M: Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia; 2006 Feb;20(2):254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
  • Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear.
  • Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM).
  • In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM.
  • WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (P<0.001).
  • In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL.
  • WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL.
  • Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Molecular Diagnostic Techniques / methods. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Age Factors. Bone Marrow / metabolism. Child. Child, Preschool. Chromosome Aberrations. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Prognosis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk Factors. Survival Analysis


31. Rothstein DH, Voss SD, Isakoff M, Puder M: Thymoma in a child: case report and review of the literature. Pediatr Surg Int; 2005 Jul;21(7):548-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymoma in a child: case report and review of the literature.
  • Thymic lesions comprise approximately 2-3% of all pediatric mediastinal tumors and include thymic cysts, hyperplasia, carcinoma, and thymomas.
  • Thymomas, which represent less than 1% of all mediastinal tumors, are rare mediastinal tumors in the pediatric population.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 May;69(5):1550-5 [10881840.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):30-3 [2049749.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):219-24 [8757387.001]
  • [Cites] Radiographics. 2002 Oct;22 Spec No:S95-S102 [12376603.001]
  • [Cites] J Pediatr Surg. 1990 Nov;25(11):1143-6 [2273428.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1994 Oct;6(4):235-9 [7803582.001]
  • [Cites] Cancer. 1994 May 15;73(10):2491-8 [8174044.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Jul-Sep;9(3):261-8 [1525005.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1405-13 [11920495.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 May;89(3):223-6 [6947681.001]
  • [Cites] Pediatr Radiol. 1993;23 (2):124-6 [8516035.001]
  • [Cites] J Pediatr Surg. 1982 Oct;17(5):512-20 [7175638.001]
  • [Cites] Ann Thorac Surg. 1978 Feb;25(2):91-8 [626543.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2280-9 [10561285.001]
  • [Cites] Thorax. 1975 Feb;30(1):19-25 [1124527.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2485-92 [7296496.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):203-7 [11465180.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):624-32 [11857293.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):562-72; discussion 572-4 [10522726.001]
  • [Cites] Ann Thorac Surg. 1991 Mar;51(3):378-84; discussion 385-6 [1998414.001]
  • (PMID = 15926048.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


32. Infante-Rivard C, Siemiatycki J, Lakhani R, Nadon L: Maternal exposure to occupational solvents and childhood leukemia. Environ Health Perspect; 2005 Jun;113(6):787-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal exposure to occupational solvents and childhood leukemia.
  • We carried out a population-based case-control study including 790 incident cases of childhood acute lymphoblastic leukemia and as many healthy controls, matched on age and sex.
  • Using an elaborate exposure coding method, this study shows that maternal exposure to solvents in the workplace does not seem to play a major role in childhood leukemia.
  • [MeSH-major] Maternal Exposure. Occupational Exposure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Solvents / toxicity
  • [MeSH-minor] Adolescent. Alkanes / toxicity. Canada / epidemiology. Case-Control Studies. Child. Child, Preschool. Female. Humans. Hydrocarbons, Aromatic / toxicity. Infant. Infant, Newborn. Male. Odds Ratio. Pregnancy

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Am J Ind Med. 2003 May;43(5):519-22 [12704624.001]
  • [Cites] Tumori. 1990 Oct 31;76(5):413-9 [2256184.001]
  • [Cites] Eur J Cancer. 1991;27(8):958-65 [1832903.001]
  • [Cites] Cancer Causes Control. 1992 Mar;3(2):161-9 [1562706.001]
  • [Cites] Am J Epidemiol. 1996 Feb 15;143(4):363-73 [8633620.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):406-19 [9498902.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:909-25 [9646055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):783-91 [10498397.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):835-8 [10952101.001]
  • [Cites] Am J Ind Med. 2000 Dec;38(6):609-18 [11071683.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):437-41 [12843769.001]
  • [Cites] Occup Environ Med. 2003 Dec;60(12):901-9 [14634180.001]
  • [Cites] J Epidemiol Community Health. 1981 Mar;35(1):11-5 [7264527.001]
  • [Cites] J Occup Med. 1982 Aug;24(8):578-84 [6750059.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1983 Dec;32:1-453 [6586639.001]
  • [Cites] Am J Epidemiol. 1985 Feb;121(2):216-24 [3860001.001]
  • [Cites] J Occup Med. 1985 Jun;27(6):420-6 [4020500.001]
  • [Cites] Arch Dis Child. 1987 Mar;62(3):279-87 [3646026.001]
  • [Cites] J Natl Cancer Inst. 1987 Jul;79(1):39-46 [3474448.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1378-84 [3621121.001]
  • [Cites] Scand J Work Environ Health. 1987 Dec;13(6):486-92 [3433050.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):13-9 [11138808.001]
  • [Cites] Am J Public Health. 2001 Apr;91(4):564-7 [11291366.001]
  • [Cites] Am J Ind Med. 2001 Jun;39(6):531-46 [11385637.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Occup Environ Med. 2002 Sep;59(9):575-93; discussion 594 [12205230.001]
  • [Cites] Am J Epidemiol. 2003 Jan 15;157(2):176-82 [12522025.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):635-44 [3164642.001]
  • (PMID = 15929905.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkanes; 0 / Hydrocarbons, Aromatic; 0 / Solvents
  • [Other-IDs] NLM/ PMC1257608
  •  go-up   go-down


33. MacKenzie J, Greaves MF, Eden TO, Clayton RA, Perry J, Wilson KS, Jarrett RF: The putative role of transforming viruses in childhood acute lymphoblastic leukemia. Haematologica; 2006 Feb;91(2):240-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The putative role of transforming viruses in childhood acute lymphoblastic leukemia.
  • Epidemiological evidence suggests that infection is involved in the etiology of common acute lymphoblastic leukemia, either by stimulating an inappropriate immune response or in the form of a classical transforming agent.
  • These results suggest that it is unlikely that a single, direct transforming agent is involved in the pathogenesis of common acute lymphoblastic leukemia.
  • [MeSH-major] Cell Transformation, Viral. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. DNA, Neoplasm / analysis. Genome, Viral. Genomics. Humans


34. Simone JV: History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract Res Clin Haematol; 2006;19(2):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] History of the treatment of childhood ALL: a paradigm for cancer cure.
  • The history of the treatment of childhood leukemia from 1950 to the present is reviewed here.
  • Strengths and weaknesses in the current treatment of childhood leukemia are discussed as well as possibilities for the future.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Therapy / history. Drug Therapy / methods. Drug Therapy / trends. Female. History, 20th Century. History, 21st Century. Humans. Male. Radiotherapy / history. Radiotherapy / methods. Radiotherapy / trends. Survival Rate / trends

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516133.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 16
  •  go-up   go-down


35. Raetz EA, Carroll WL: Eliminating a gold standard in childhood acute lymphoblastic leukemia? Pediatr Blood Cancer; 2006 Sep;47(3):242-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eliminating a gold standard in childhood acute lymphoblastic leukemia?
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


36. Riedt T, Ebinger M, Salih HR, Tomiuk J, Handgretinger R, Kanz L, Grünebach F, Lengerke C: Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia. Blood; 2009 Apr 23;113(17):4049-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia.
  • Consistent with the notion that embryonic pathways can reactivate during adult oncogenesis, recent studies suggest involvement of CDX2 in human acute myeloid leukemia (AML).
  • Here we study CDX2 in healthy and leukemic human lymphoid cells, and show that a majority of leukemic samples display various degrees of aberrant CDX2 expression.
  • Analysis of a cohort of 37 childhood acute lymphoblastic leukemia (ALL) patients treated in our hospital reveals that high CDX2 expression levels at diagnosis correlate with persistence of minimal residual disease (MRD) during the course of treatment.
  • Thus, CDX2 expression levels may serve as a marker for adverse prognosis in pediatric ALL.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Homeodomain Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Case-Control Studies. Child. Humans. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218548.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


37. Kesler SR, Tanaka H, Koovakkattu D: Cognitive reserve and brain volumes in pediatric acute lymphoblastic leukemia. Brain Imaging Behav; 2010 Dec;4(3-4):256-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive reserve and brain volumes in pediatric acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is associated with long-term, progressive cognitive deficits and white matter injury.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):837-43 [19117694.001]
  • [Cites] Pediatr Blood Cancer. 2009 Aug;53(2):156-61 [19405135.001]
  • [Cites] Hum Genet. 2009 Jul;126(1):215-32 [19294424.001]
  • [Cites] Neurology. 2009 Aug 4;73(5):356-61 [19652139.001]
  • [Cites] Ann N Y Acad Sci. 2009 Aug;1172:63-9 [19743551.001]
  • [Cites] Brain Res Rev. 2009 Oct;61(2):221-39 [19631687.001]
  • [Cites] Acta Neurochir Suppl. 2010;106:195-7 [19812948.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Oct;23(5):1065-82, vi-vii [19825453.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Nov;30(10):1947-54 [19643920.001]
  • [Cites] Prog Neurobiol. 2009 Dec;89(4):369-82 [19819293.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):70-85 [19657332.001]
  • [Cites] J Int Neuropsychol Soc. 2010 Jan;16(1):94-105 [19835663.001]
  • [Cites] Lang Speech Hear Serv Sch. 2010 Jan;41(1):70-83 [19948772.001]
  • [Cites] J Head Trauma Rehabil. 2010 Jan-Feb;25(1):15-22 [20051899.001]
  • [Cites] J Clin Exp Neuropsychol. 2009 Oct;31(7):868-76 [19333862.001]
  • [Cites] J Pediatr Psychol. 2010 Jul;35(6):662-71 [19820170.001]
  • [Cites] Pediatrics. 2005 Aug;116(2):333-41 [16061586.001]
  • [Cites] J Pediatr. 2006 Jan;148(1):72-7 [16423601.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3 Suppl 2):S69-74 [16917199.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):456-61 [11070477.001]
  • [Cites] J Int Neuropsychol Soc. 2001 Jul;7(5):640-6 [11459115.001]
  • [Cites] Neuroimage. 2001 Jul;14(1 Pt 1):21-36 [11525331.001]
  • [Cites] Dev Neuropsychol. 2002;21(2):173-95 [12139198.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):88-92 [12461791.001]
  • [Cites] Dev Neuropsychol. 2002;22(2):455-69 [12537333.001]
  • [Cites] J Clin Exp Neuropsychol. 2003 Aug;25(5):594-613 [12815498.001]
  • [Cites] J Clin Exp Neuropsychol. 2003 Aug;25(5):625-33 [12815500.001]
  • [Cites] Neuroimage. 2003 Jul;19(3):1215-27 [12880846.001]
  • [Cites] Appl Neuropsychol. 2003;10(3):153-62 [12890641.001]
  • [Cites] Psychol Sci. 2003 Nov;14(6):623-8 [14629696.001]
  • [Cites] Radiology. 2003 Dec;229(3):659-69 [14576448.001]
  • [Cites] Nat Rev Neurosci. 2004 Jun;5(6):471-82 [15152197.001]
  • [Cites] Int J Methods Psychiatr Res. 2004;13(3):141-51 [15297898.001]
  • [Cites] J Pediatr. 1992 Dec;121(6):885-9 [1447650.001]
  • [Cites] Demography. 1998 Feb;35(1):71-81 [9512911.001]
  • [Cites] Am J Phys Med Rehabil. 2005 Jan;84(1):62-75 [15632490.001]
  • [Cites] Cereb Cortex. 2005 Apr;15(4):394-402 [15749983.001]
  • [Cites] J Child Neurol. 2005 Feb;20(2):129-33 [15794179.001]
  • [Cites] Pharmacotherapy. 2005 May;25(5):748-55 [15899736.001]
  • [Cites] J Fam Psychol. 2005 Jun;19(2):294-304 [15982107.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):281-90 [15806539.001]
  • [Cites] Prog Brain Res. 2006;157:199-206 [17046672.001]
  • [Cites] Arch Clin Neuropsychol. 2006 Oct;21(7):711-20 [17071362.001]
  • [Cites] Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007 Jan;14(1):40-54 [17164189.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1082-7 [17219132.001]
  • [Cites] Gerontologist. 2007 Jun;47(3):307-22 [17565095.001]
  • [Cites] Clin Neuropsychol. 2007 Jul;21(4):638-52 [17613982.001]
  • [Cites] Dev Psychol. 2007 Nov;43(6):1497-512 [18020827.001]
  • [Cites] J Pediatr. 2008 Apr;152(4):513-20, 520.e1 [18346506.001]
  • [Cites] Curr Opin Psychiatry. 2008 May;21(3):296-302 [18382231.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):792-7 [18184841.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):99-104 [18322925.001]
  • [Cites] J Magn Reson Imaging. 2008 Jun;27(6):1250-5 [18504742.001]
  • [Cites] Neuroimage. 2008 Jul 1;41(3):903-13 [18424084.001]
  • [Cites] Behav Brain Res. 2008 Sep 1;192(1):137-42 [18378330.001]
  • [Cites] J Consult Clin Psychol. 2008 Jun;76(3):367-78 [18540731.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3025-30 [18565888.001]
  • [Cites] J Int Neuropsychol Soc. 2008 Sep;14(5):869-77 [18764982.001]
  • [Cites] Dev Neurorehabil. 2008 Jul;11(3):174-86 [18781502.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2691-700 [18491104.001]
  • [Cites] Dev Disabil Res Rev. 2008;14(3):185-95 [18924154.001]
  • [Cites] Prog Neurobiol. 2008 Nov;86(3):141-55 [18824075.001]
  • [Cites] Acta Paediatr. 2009 Jan;98(1):180-6 [18826490.001]
  • [Cites] Biol Psychol. 2009 Feb;80(2):256-9 [19022337.001]
  • [Cites] Pediatr Blood Cancer. 2009 Apr;52(4):447-54 [19061221.001]
  • [Cites] Am J Geriatr Psychiatry. 2009 Mar;17(3):175-8 [19225275.001]
  • [Cites] J Neurosci. 2009 Feb 18;29(7):2212-24 [19228974.001]
  • [Cites] J Pediatr Psychol. 2009 Apr;34(3):317-27 [18667478.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):465-70 [19395901.001]
  • [Cites] Neurobiol Aging. 2009 Jul;30(7):1114-24 [18053618.001]
  • [Cites] Neuropsychologia. 2009 Aug;47(10):2015-28 [19467352.001]
  • [Cites] Behav Genet. 2009 Jul;39(4):393-405 [19377873.001]
  • (PMID = 20814845.001).
  • [ISSN] 1931-7565
  • [Journal-full-title] Brain imaging and behavior
  • [ISO-abbreviation] Brain Imaging Behav
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA134639-01A1; United States / NCI NIH HHS / CA / K07 CA134639; United States / NICHD NIH HHS / HD / R24 HD050836; United States / NCI NIH HHS / CA / K07 CA134639-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS275369; NLM/ PMC3049995
  •  go-up   go-down


38. Hosking FJ, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Taylor M, Tomlinson IP, Greaves M, Houlston RS: Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. Blood; 2010 Jun 3;115(22):4472-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk.
  • To examine whether homozygosity is associated with an increased risk of developing childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), we analyzed 824 ALL cases and 2398 controls genotyped for 292 200 tagging SNPs.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231427.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / 10417; United Kingdom / Cancer Research UK / / C1298/A8362
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Erythropoietin
  •  go-up   go-down


39. Rai SN, Hudson MM, McCammon E, Carbone L, Tylavsky F, Smith K, Surprise H, Shelso J, Pui CH, Kaste S: Implementing an intervention to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-controlled double-blind randomized interventional longitudinal study design. Contemp Clin Trials; 2008 Sep;29(5):711-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implementing an intervention to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-controlled double-blind randomized interventional longitudinal study design.
  • The baseline study (Study 1) aims to estimate the prevalence of diminished bone mineral density (BMD) in patients treated for childhood acute lymphoblastic leukemia (ALL) and identify risk factors for BMD deficits.
  • The extensive information being collected through this large study will serve as a repository of relational data about BMD and bone turnover and will support further investigations to assess the association of calcium metabolism, bone turnover, nutritional intake, lifestyle factors (such as exercise and the use of alcohol and tobacco), and the specific agents used in ALL therapy in this rapidly increasing population of childhood cancer survivors.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1999 Nov;33(5):455-61 [10531569.001]
  • [Cites] Pediatr Blood Cancer. 2008 May;50(5):1032-8 [17570705.001]
  • [Cites] J Bone Miner Res. 1999 Dec;14(12):2010-4 [10620059.001]
  • [Cites] Int J Clin Pract. 1998 Nov-Dec;52(8):557-65 [10622055.001]
  • [Cites] Stat Med. 2000 Jan 30;19(2):205-20 [10641025.001]
  • [Cites] Osteoporos Int. 2000;11(4):281-94 [10928217.001]
  • [Cites] Med Pediatr Oncol. 2000 Oct;35(4):415-20 [11025472.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Leukemia. 2001 May;15(5):728-34 [11368432.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001 Jul-Aug;14(7):817-32 [11515724.001]
  • [Cites] J Pediatr. 2002 Aug;141(2):204-10 [12183715.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Mar;16 Suppl 2:343-53 [12729414.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):435-41 [14716354.001]
  • [Cites] Pediatr Radiol. 2004 May;34(5):373-8; quiz 443-4 [14963622.001]
  • [Cites] Sports Med. 2005;35(9):779-830 [16138787.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):182-3; discussion 184 [15236291.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Chronic Dis. 1974 Sep;27(7-8):365-75 [4612056.001]
  • [Cites] Biometrics. 1989 Sep;45(3):939-55 [2486189.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):61-6 [1670723.001]
  • [Cites] JAMA. 1993 Aug 18;270(7):841-4 [8340983.001]
  • [Cites] Biometrics. 1997 Sep;53(3):937-47 [9290224.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):234-40 [9628435.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3174-81 [10487683.001]
  • [Cites] Int J Sports Med. 2005 Jun;26(5):332-8 [15895314.001]
  • [Cites] Am J Clin Nutr. 2005 Nov;82(5):1115-26; quiz 1147-8 [16280447.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):77-87 [16106430.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Calcif Tissue Int. 2006 Feb;78(2):65-71 [16467972.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(2):CD005119 [16625624.001]
  • [Cites] J Pediatr. 2006 Jun;148(6):793-9 [16769389.001]
  • [Cites] Genes Dev. 2006 Sep 15;20(18):2492-506 [16980579.001]
  • [Cites] BMJ. 2006 Oct 14;333(7572):775 [16980314.001]
  • [Cites] J Child Health Care. 2006 Dec;10(4):337-50 [17101625.001]
  • [Cites] Arch Pediatr Adolesc Med. 2006 Dec;160(12):1269-76 [17146025.001]
  • [Cites] J Bone Miner Res. 2007 Mar;22(3):458-64 [17181396.001]
  • [Cites] J Bone Miner Res. 2007 Mar;22(3):434-46 [17181400.001]
  • [Cites] Int J Sport Nutr Exerc Metab. 2006 Dec;16(6):580-96 [17342880.001]
  • [Cites] J Bone Miner Res. 2007 Apr;22(4):527-36 [17227221.001]
  • [Cites] J Phys Act Health. 2007 Jan;4(1):17-29 [17489004.001]
  • [Cites] J Bone Miner Res. 1999 Dec;14(12):2002-9 [10620058.001]
  • (PMID = 18586578.001).
  • [ISSN] 1559-2030
  • [Journal-full-title] Contemporary clinical trials
  • [ISO-abbreviation] Contemp Clin Trials
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA-21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / CA020180-209003; United States / NCI NIH HHS / CA / P01 CA020180; United States / NCI NIH HHS / CA / P01 CA020180-209003
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS69260; NLM/ PMC2613024
  •  go-up   go-down


40. Xiao PF, Chai YH, Li JQ, He HL, Wang Y, Li ZP, He YX, Ji ZH: [Therapeutic effectiveness of CCLG-97 protocol on standard-risk childhood acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2005 Jul;43(7):486-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effectiveness of CCLG-97 protocol on standard-risk childhood acute lymphoblastic leukemia].
  • OBJECTIVE: With the improvement of the diagnosis and treatment, the complete remission (CR) rate and the survival rate of childhood acute lymphoblastic leukemia have been increased in the recent 10 years.
  • The objective of this study was to analyze the outcomes of 119 standard-risk childhood acute lymphoblastic leukemia (SR-ALL) patients, and explore how to improve the survival rate in ALL.
  • METHODS: A total of 119 patients aged 14 months to 15 years were diagnosed as SR-ALL according to the Suggestion of Diagnosis And Treatment for Childhood Acute Leukemia-1993.
  • CONCLUSION: Reinforcing administration and regular therapy are important to improve the long-term survival rate in childhood ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control
  • [MeSH-minor] Adolescent. Child. Child, Preschool. China. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Remission Induction / methods. Risk Factors. Secondary Prevention. Survival Rate. Time Factors. Treatment Outcome


41. Styczynski J, Koltan A, Wysocki M: Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis. Neoplasma; 2006;53(2):168-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
  • Resistance to glucocorticoids remains one of the main obstacles in therapy of childhood acute lymphoblastic leukemia (ALL).
  • The aim of the study was the analysis of relationship between ex vivo drug resistance of prednisolone and dexamethasone and exposure to these drugs in childhood ALL, with respect to risk factor analysis.
  • Risk factor analysis showed that concentration of prednisolone and dexamethasone higher than respective ex vivo drug resistance, is a strongest prognostic factor in childhood ALL.
  • [MeSH-major] Drug Resistance, Neoplasm / physiology. Glucocorticoids / pharmacokinetics. Glucocorticoids / therapeutic use. Models, Theoretical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / pharmacokinetics. Apoptosis / physiology. Asparaginase / pharmacokinetics. Body Fluids / chemistry. Child. Child, Preschool. Disease-Free Survival. Factor Analysis, Statistical. Female. Humans. Infant. Lethal Dose 50. Male. P-Glycoproteins / biosynthesis. Prognosis. Risk Factors. Survival Analysis. Vincristine / pharmacokinetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575474.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / P-Glycoproteins; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


42. Rimmer RB, Weigand S, Foster KN, Wadsworth MM, Jacober K, Matthews MR, Drachman D, Caruso DM: Scald burns in young children--a review of Arizona burn center pediatric patients and a proposal for prevention in the Hispanic community. J Burn Care Res; 2008 Jul-Aug;29(4):595-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scald burns in young children--a review of Arizona burn center pediatric patients and a proposal for prevention in the Hispanic community.
  • Arizona Burn Center staff observed an increasing number of pediatric scald burn admissions.
  • Arizona Burn Center scald admission variables (ages 0-5 years) reviewed included age, sex, ethnicity, TBSA, body parts burned, occurrence month and location, caregiver present, child and caregiver activities when injured, payor source, length of stay, parental language, and zip code.
  • There were a total of 170 pediatric patients, aged 0 to 5 years, admitted to the burn center during 2005 to 2006.
  • Of this total, 124 of the patients were admitted for scald burns, accounting for 59% of all pediatric burn admissions.
  • The remaining pediatric admissions for children aged 0 to 5 were for burns caused by fire or flame 15%, contact with a hot object 13%, friction burns 7%, chemical burns 3%, and electrical burns 3%.
  • Most common child behaviors were pulling hot substance from stove (24%), from countertop (13%), and having liquid spilled on them (13%) typically while caregiver was cooking.
  • Scalds occurred in the kitchen (83%) and mainly in child's home (94%).
  • Results suggest that culturally sensitive, bilingual scald prevention education, targeting Hispanics, is needed to create awareness of the frequency, severity, and danger associated with pediatric scalds.
  • [MeSH-minor] Accidents, Home / statistics & numerical data. Arizona / epidemiology. Burn Units. Child, Preschool. Cooking. Female. Focus Groups. Health Education. Humans. Infant. Infant, Newborn. Injury Severity Score. Length of Stay / statistics & numerical data. Male. Patient Admission / statistics & numerical data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535476.001).
  • [ISSN] 1559-047X
  • [Journal-full-title] Journal of burn care & research : official publication of the American Burn Association
  • [ISO-abbreviation] J Burn Care Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Addeo R, Caraglia M, Baldi A, D'Angelo V, Casale F, Crisci S, Abbruzzese A, Vincenze B, Campioni M, Di Tullio MT, Indolfi P: Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL). Cancer Biol Ther; 2005 Jan;4(1):32-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL).
  • Molecular parameters involved in the prediction of response of childhood acute lymphoblastic leukemia (ALL) are still unclear.
  • We have evaluated the expression and mutational status of p53 and the expression of bcl-x(L) and bax in a series of 62 consecutive children (median age: 4 years; 38 males and 24 females) affected by de novo ALL.
  • OS was directly correlated with age<6 years (p=0.0004), female gender (p=0.0139), nonT phenotype (p=0.0012), WBC at diagnosis<or=20000/microl (p=0.0187), response to induction therapy with prednisone (p=0.0211), wild type p53 or low expression of p53 (p=0.035).
  • [MeSH-major] Gene Expression Profiling. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adolescent. Apoptosis. Child. Child, Preschool. Female. Genes. Humans. Infant. Infant, Newborn. Male. Prognosis. Survival Analysis. bcl-X Protein


44. Badell I, Muñoz A, Estella J, Fernández-Delgado R, Javier G, Verdeguer A, Cubells J, SHOP Leukemia and Lymphoma Studies Committee (Spanish Societies of Pediatric Hematology and Pediatric Oncology): Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998. Clin Transl Oncol; 2008 Feb;10(2):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998.
  • INTRODUCTION: The first multi-centric protocol for childhood acute lymphoblastic leukaemia (ALL) treatment in Spain started in 1989 and was conducted by the Spanish Pediatric Hematology and Oncology Societies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Disease-Free Survival. Hematopoietic Stem Cell Transplantation. Humans. Infant. Kaplan-Meier Estimate. Time. Transplantation, Autologous. Treatment Outcome


45. Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R: Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia; 2005 Feb;19(2):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.
  • [MeSH-major] Genes, ras. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Child. Child, Preschool. Exons. Female. Humans. Infant. Male. Mutation

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2008 Aug;22(8):1619-21 [18273045.001]
  • (PMID = 15538400.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


46. Malempati S, Tibbitts D, Cunningham M, Akkari Y, Olson S, Fan G, Sears RC: Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia; 2006 Sep;20(9):1572-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias.
  • We examined whether aberrant protein stabilization could be a mechanism of c-Myc overexpression in leukemia cell lines and in primary bone marrow samples from pediatric acute lymphoblastic leukemia (ALL) patients.
  • We found that c-Myc protein half-life was prolonged in the majority of leukemia cell lines and bone marrow samples tested.
  • There were no mutations in the c-myc gene in any of the leukemia cell lines that could account for increased c-Myc stability.
  • However, abnormal phosphorylation at two conserved sites, Threonine 58 and Serine 62, was observed in leukemia cell lines with stabilized c-Myc.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2104-10 [10706881.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32475-81 [10913153.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2275-84 [12399973.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25802-7 [12734207.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1833-41 [12714522.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51606-12 [14563837.001]
  • [Cites] Nat Cell Biol. 2004 Apr;6(4):308-18 [15048125.001]
  • [Cites] EMBO J. 2004 May 19;23(10):2116-25 [15103331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90 [15150404.001]
  • [Cites] Nature. 1982 Sep 2;299(5878):61-3 [6955596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Nature. 1983 Aug 18-24;304(5927):596-602 [6308472.001]
  • [Cites] Cell. 1983 Dec;35(3 Pt 2):603-10 [6606489.001]
  • [Cites] Blood. 1984 Dec;64(6):1234-9 [6208953.001]
  • [Cites] Mol Cell Biol. 1984 Nov;4(11):2486-97 [6513926.001]
  • [Cites] Nature. 1986 Aug 28-Sep 3;322(6082):848-50 [3528863.001]
  • [Cites] Annu Rev Genet. 1986;20:361-84 [3028245.001]
  • [Cites] Mol Cell Biol. 1987 Dec;7(12):4513-21 [3325826.001]
  • [Cites] Curr Top Microbiol Immunol. 1988;141:82-93 [3215058.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):3952-64 [2196440.001]
  • [Cites] Genes Dev. 1990 Dec;4(12A):2025-35 [2269425.001]
  • [Cites] Oncogene. 1991 May;6(5):797-805 [2052358.001]
  • [Cites] Genes Dev. 1993 Apr;7(4):671-82 [8458579.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3383-6 [8012955.001]
  • [Cites] Mol Cell Biol. 1994 Aug;14(8):5510-22 [8035827.001]
  • [Cites] Blood. 1994 Aug 1;84(3):883-8 [8043869.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):785-9 [8524413.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2439-44 [8570196.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5513-8 [8621409.001]
  • [Cites] Mol Cell Biol. 1998 Oct;18(10):5961-9 [9742113.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):717-26 [9927431.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):185-93 [9931326.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):169-79 [10078200.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8571-80 [15467756.001]
  • [Cites] Cell Cycle. 2004 Sep;3(9):1133-7 [15467447.001]
  • [Cites] EMBO J. 2005 Apr 20;24(8):1571-83 [15791206.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2423-35 [10713166.001]
  • (PMID = 16855632.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100855-02; United States / NCI NIH HHS / CA / CA086957-05; United States / NCI NIH HHS / CA / R01 CA100855; United States / NCI NIH HHS / CA / CA100855-02; United States / NCI NIH HHS / CA / K01 CA086957; United States / NCI NIH HHS / CA / K01 CA086957-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 3.4.99.- / ATP dependent 26S protease
  • [Other-IDs] NLM/ NIHMS42996; NLM/ PMC2322939
  •  go-up   go-down


47. Hammer LD, Curry ES, Harlor AD, Laughlin JJ, Leeds AJ, Lessin HR, Rodgers CT, Granado-Villar DC, Brown JM, Cotton WH, Gaines BM, Gambon TB, Gitterman BA, Gorski PA, Kraft CA, Marino RV, Paz-Soldan GJ, Zind B, Committee on Practice and Ambulatory Medicine, Council on Community Pediatrics: Increasing immunization coverage. Pediatrics; 2010 Jun;125(6):1295-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from the 2007 National Immunization Survey showed that 90% of children 19 to 35 months of age have received recommended doses of each of the following vaccines: inactivated poliovirus (IPV), measles-mumps-rubella (MMR), varicella-zoster virus (VZB), hepatitis B virus (HBV), and Haemophilus influenzae type b (Hib).
  • These challenges include an increase in new vaccines and new vaccine combinations as well as a significant number of vaccines currently under development; a dramatic increase in the acquisition cost of vaccines, coupled with a lack of adequate payment to practitioners to buy and administer vaccines; unanticipated manufacturing and delivery problems that have caused significant shortages of various vaccine products; and the rise of a public antivaccination movement that uses the Internet as well as standard media outlets to advance a position, wholly unsupported by any scientific evidence, linking vaccines with various childhood conditions, particularly autism.
  • Pediatricians should work individually and collectively at the local, state, and national levels to ensure that all children without a valid contraindication receive all childhood immunizations on time.
  • Pediatricians and pediatric organizations, in conjunction with government agencies such as the Centers for Disease Control and Prevention, must communicate effectively with parents to maximize their understanding of the overall safety and efficacy of vaccines.
  • [MeSH-minor] Child. Financing, Government / economics. Financing, Government / statistics & numerical data. Health Services Accessibility / economics. Healthy People Programs / standards. Humans. Immunization Schedule. Insurance Coverage. Practice Management, Medical / organization & administration. Public Sector / economics. Vaccines / economics


48. Maruyama T, Yamamoto S, Nojima M, Morita N, Tanizawa T, Shima H: Extramedullary relapse of acute lymphoblastic leukemia in childhood to the prostate. Int J Urol; 2007 May;14(5):447-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of acute lymphoblastic leukemia in childhood to the prostate.
  • He had a past history of acute lymphoblastic leukemia (ALL), which subsided in response to chemotherapy at 3 years of age.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Child. Humans. Male. Recurrence


49. Mata JF, Silveira VS, Mateo EC, Cortez MA, Queiroz RG, Yunes JA, Lee ML, Toledo SR, Petrilli AS, Brandalise SR, Tone LG, Scrideli CA: Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer; 2010 Jul 15;55(1):100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL).
  • The objective of the present study was to assess the expression profile of key apoptosis-related genes in terms of clinical and biological variables and of the survival of children with acute lymphoblastic leukemia (ALL).
  • CONCLUSION: These findings suggest an association between lower expression levels of the pro-apoptotic genes and a poor response to induction therapy at day 7 and prognosis in childhood ALL.
  • [MeSH-major] Antigens, CD95 / genetics. Caspase 3 / genetics. Caspase 8 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression Profiling. Humans. Immunophenotyping. Infant. Leukocyte Count. Male. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Survival Rate


50. Bourquin JP, Izraeli S: Where can biology of childhood ALL be attacked by new compounds? Cancer Treat Rev; 2010 Jun;36(4):298-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where can biology of childhood ALL be attacked by new compounds?
  • Although the majority of children with acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy, the challenge remains to salvage patients with resistant disease and to reduce treatment related toxicity.
  • Here we review the principles of current ALL therapy, recent advances in understanding ALL biology and discuss a selection of promising areas for drug development that may take advantage of the underlying leukemia biology.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Cell Differentiation / drug effects. Cell Survival / drug effects. Child. Drug Resistance, Neoplasm. Humans. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. TOR Serine-Threonine Kinases

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20223597.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 146
  •  go-up   go-down


51. Goshen Y, Stark B, Kornreich L, Michowiz S, Feinmesser M, Yaniv I: High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Sep;49(3):294-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Most survivors of childhood acute lymphoblastic leukemia (ALL) and T-cell lymphoma (T-NHL) treated before 1990 received cranial radiation.
  • CONCLUSIONS: Survivors of childhood ALL treated with cranial radiation require prolonged surveillance because of a high incidence of late meningiomas.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Incidence. Israel / epidemiology. Male


52. Hamouda F, El-Sissy AH, Radwan AK, Hussein H, Gadallah FH, Al-Sharkawy N, Sedhom E, Ebeid E, Salem SI: Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt. J Egypt Natl Canc Inst; 2007 Jun;19(2):87-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt.
  • [MeSH-major] Antigens, Neoplasm / analysis. Immunophenotyping / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Case-Control Studies. Child. Chromosome Banding. Diploidy. Egypt. Female. Flow Cytometry. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Prognosis. Retrospective Studies. Universities


53. Harila MJ, Winqvist S, Lanning M, Bloigu R, Harila-Saari AH: Progressive neurocognitive impairment in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2009 Aug;53(2):156-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive neurocognitive impairment in young adult survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Despite the extensive literature on neuropsychological sequelae after treatment of childhood acute lymphoblastic leukemia (ALL), the very-long-term neurocognitive outcome of the survivors is poorly studied.
  • We assessed neuropsychological functioning in a population-based cohort of young adult childhood ALL survivors.
  • CONCLUSIONS: Survivors of childhood ALL suffer from long-lasting progressive neuropsychological impairment, especially when treatment includes cranial irradiation.
  • [MeSH-major] Brain Neoplasms / complications. Cognition Disorders / epidemiology. Cognition Disorders / etiology. Cranial Irradiation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Antineoplastic Agents / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Male. Neuropsychological Tests. Survivors. Young Adult


54. Nurzyńska-Flak J, Kowalczyk JR: [Incidence of childhood leukemia in the Lublin region of Poland in 1988-2000]. Wiad Lek; 2005;58(5-6):284-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of childhood leukemia in the Lublin region of Poland in 1988-2000].
  • Purpose of the work was the analysis of the number and structure of leukemia in children living in the Lublin Region of Poland.
  • Among leukemias, according to the International Classification of Childhood Cancers, were counted: lymphoid leukemia, acute non-lymphocytic leukemia, chronic myeloid leukemia, other specified and unspecified leukemias.
  • RESULTS: 244 cases of leukemia were reported (152 boys--62.3% and 92 girls--37.7%).
  • CONCLUSIONS: In the Lublin Region lower percentage of leukemia was observed compared to the values determined for the country.
  • Incidence of leukemia was falling, but the analysis in age-groups proved, that it was caused by the decreasing incidence in children under 5 year.
  • [MeSH-major] Leukemia / epidemiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Incidence. Infant. Male. Poland / epidemiology. Rural Population / statistics & numerical data. Urban Population / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238118.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


55. Attarbaschi A, Mann G, König M, Steiner M, Dworzak MN, Gadner H, Haas OA, Austrian Berlin-Frankfurt-Münster Cooperative Study Group: Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases. Genes Chromosomes Cancer; 2006 Jun;45(6):608-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases.
  • Near-tetraploidy (82-94 chromosomes) makes up fewer than 1% of childhood acute lymphoblastic leukemia (ALL) cases and has been reportedly associated with a possibly poorer prognosis compared with other ploidy groups.
  • Fluorescence in situ hybridization revealed that eight of the nine B-cell precursor (BCP) cases and none of the three T-cell ALL cases had an ETV6/RUNX1 rearrangement.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / analysis. Polyploidy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / analysis. Repressor Proteins / analysis
  • [MeSH-minor] Adolescent. Austria. Child. Child, Preschool. Cytogenetic Analysis. Humans. In Situ Hybridization, Fluorescence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Genetic Alliance. consumer health - Tetraploidy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16552772.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


56. Guise JM, Austin D, Morris CD: Review of case-control studies related to breastfeeding and reduced risk of childhood leukemia. Pediatrics; 2005 Nov;116(5):e724-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of case-control studies related to breastfeeding and reduced risk of childhood leukemia.
  • OBJECTIVE: To conduct a systematic review to evaluate the evidence for the effect of breastfeeding on the risk of developing childhood leukemia.
  • REVIEW METHODS: We sought studies providing data regarding the association of breastfeeding and occurrence of childhood leukemia.
  • Of the 10 studies reviewed, only 4 were sufficient to provide at least fair-quality evidence regarding the association between maternal breastfeeding and childhood leukemia.
  • Studies conflicted regarding the protective effect of breastfeeding on childhood leukemia.
  • Taken together, half of the studies associated breastfeeding with a lower risk of acute lymphocytic leukemia.
  • CONCLUSIONS: There are few high-quality studies that examine the potential for a protective effect of breastfeeding for childhood leukemia.
  • It is estimated that the United States spends 1.4 billion dollars annually on the treatment of childhood leukemia.
  • [MeSH-major] Breast Feeding. Leukemia / prevention & control
  • [MeSH-minor] Case-Control Studies. Child. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Risk Reduction Behavior

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263987.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / PHS HHS / / 0990-0115; United States / AHRQ HHS / HS / 1 K08 HS11338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


57. Fangusaro J: Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol; 2009 Nov;24(11):1409-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas.
  • Pediatric high-grade gliomas represent approximately 10% of all pediatric brain tumors.
  • In this review, we present an overview of both pediatric high-grade gliomas and diffuse intrinsic pontine gliomas with a focus on their epidemiology, etiology, presentation, prognostic factors, biology, treatment modalities, outcomes, and future research directions.
  • [MeSH-minor] Child. Humans. Models, Neurological. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638636.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


58. Tumer TB, Yilmaz D, Tanrikut C, Sahin G, Ulusoy G, Arinç E: DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia. Leuk Res; 2010 Oct;34(10):1275-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia.
  • In this study, we investigated the possible association of X-ray repair cross-complimenting group 1 (XRCC1) Arg399Gln and Arg194Trp variants with the risk of incidence of childhood acute lymphoblastic leukemia (ALL) in Turkish population comprised of 190 healthy controls and 167 ALL patients.
  • In case of codon 194 polymorphism, no significant associations have been found with risk of childhood ALL.
  • In addition, none of the combinations of XRCC1 codon 194 and 399 polymorphisms have been found to be significantly associated with childhood ALL risk.
  • In the scope of this study, we have also showed that the co-presence of XRCC1 codon 399 and CYP2E1*5B and *6 polymorphisms (data for CYP2E1 polymorphisms drawn from previously published study conducted in our lab) in the same individuals considerably increased the risk for childhood ALL to 3.7-fold with borderline significance (p=0.049).
  • This is the first study showing combined associations of XRCC1 399Gln, CYP2E1*5B and *6 alleles with the risk of development of childhood ALL.
  • [MeSH-major] Cytochrome P-450 CYP2E1 / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. DNA Damage. DNA Repair. Female. Humans. Infant. Male. Risk

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20394984.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 1.14.13.- / Cytochrome P-450 CYP2E1
  •  go-up   go-down


59. Tie LJ, Gu LJ, Jiang LM, Zhao JC, Chen J, Pan C, Dong L, Chen J, Xue HL, Tang JY, Wang YP: [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr;11(4):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
  • OBJECTIVE: Minimal residual disease (MRD) is one of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL).
  • Using sets of combined antibodies, immunophenotypic expression of leukemia cells was observed in 95 of 106 B-lineage ALL cases (89.6%).
  • [MeSH-major] Flow Cytometry / methods. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Child. Gene Rearrangement, T-Lymphocyte. Humans. Immunophenotyping. Neoplasm, Residual

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374803.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


60. Wang J, Zhan P, Chen B, Zhou R, Yang Y, Ouyang J: MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Res; 2010 Dec;34(12):1596-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: a meta-analysis.
  • To date, case-control studies on the association between methylenetetrahydrofolate reductase (MTHFR) C677T and childhood acute lymphoblastic leukemia have provided either controversial or inconclusive results.
  • To clarify the effect of MTHFR C677T on the risk of childhood acute lymphoblastic leukemia, a meta-analysis of all case-control observational studies was performed.
  • The random effects (RE) model showed that the 677T allele was not associated with a decreased susceptibility risk of childhood acute lymphoblastic leukemia compared with the C allele [OR=0.96, 95% confidence interval (CI) (0.88-1.04), P=0.34].
  • Although MTHFR C677T was associated with increased risks of colorectal cancer, leukemia, and gastric cancer, our pooled data suggest no evidence for a major role of MTHFR C677T in the carcinogenesis of childhood acute lymphoblastic leukemia.
  • [MeSH-major] Alleles. Methylenetetrahydrofolate Dehydrogenase (NADP) / genetics. Models, Biological. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Case-Control Studies. Child. Child, Preschool. Colorectal Neoplasms / genetics. Female. Homozygote. Humans. Male. Predictive Value of Tests. Risk Factors. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20409583.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.5 / Methylenetetrahydrofolate Dehydrogenase (NADP)
  •  go-up   go-down


61. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR, International BFM Study Group (I-BFM-SG): Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia; 2008 Apr;22(4):771-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
  • Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Gene Rearrangement. Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Gene Rearrangement, T-Lymphocyte. Genes, Immunoglobulin / genetics. Humans. Infant. Polymerase Chain Reaction. Risk Assessment


62. Kroll ME, Draper GJ, Stiller CA, Murphy MF: Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics. J Natl Cancer Inst; 2006 Mar 15;98(6):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics.
  • We investigated time trends in childhood leukemia by using Poisson regression methods to analyze data from the National Registry of Childhood Tumours, a long-standing high-quality registry that covers the whole childhood population of Britain.
  • During 1974-2000, the average annual percentage change in rate (AAC) of childhood acute lymphoblastic leukemia (ALL) in Britain was 0.7% (95% confidence interval [CI] = 0.4 to 1.0).
  • This increase was apparently driven by the "common" subtype (expressing the CD10 antigen) of precursor B-cell ALL, for which the estimated AAC during 1980-1996 was 1.4% (95% CI = 0.8 to 2.0).
  • There was no statistically significant time trend in other subtypes of ALL combined (1980-1996) or in acute myeloid leukemia (1974-2000).
  • These results are consistent with hypotheses that some childhood leukemia may be triggered by infection occurring close to the time of diagnosis of leukemia, particularly in conditions of low herd immunity, and raise the possibility that contact with influenza shortly before the diagnosis of leukemia may sometimes be involved.
  • [MeSH-major] Disease Outbreaks. Influenza, Human / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Adolescent. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / virology. Child. Female. Great Britain / epidemiology. Humans. Incidence. Male. Poisson Distribution. Registries

  • MedlinePlus Health Information. consumer health - Flu.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2006 Dec 6;98(23):1746; author reply 1746-7 [17148778.001]
  • (PMID = 16537835.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Graubner UB, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G, Janka GE: Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Feb;50(2):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia.
  • BACKGROUND: Infections are a major cause of morbidity and mortality in childhood acute lymphoblastic leukemia (ALL) and only limited information is available on infectious complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Infection / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Infant. Male. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17635005.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Révész T, van Dongen JJ, van der Velden VH, Schilham MW: Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia; 2010 Aug;24(8):1462-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.
  • Relapse of pediatric acute lymphoblastic leukemia (ALL) remains the main cause of treatment failure after allogeneic stem cell transplantation (alloSCT).
  • However, in contrast with the usual early recurrence of leukemia, relapses were delayed up to 3 years after SCT.
  • In addition, several relapses presented at unusual extramedullary sites suggesting that the immune intervention may have altered the pattern of leukemia recurrence.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Male. Risk


66. Milne E, Laurvick CL, de Klerk N, Robertson L, Thompson JR, Bower C: Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006. Int J Cancer; 2008 Mar 1;122(5):1130-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006.
  • Increases in the incidence of childhood acute lymphoblastic leukemia (ALL) have been reported in some countries, while other reports from similar geographical regions have indicated stable rates.
  • We used population-based data from Western Australia to investigate trends in the incidence of childhood ALL between 1960 and 2006.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Australia / epidemiology. Child. Child, Preschool. Female. Humans. Incidence. Male. Registries


67. Nyári TA, Kajtár P, Bartyik K, Thurzó L, McNally R, Parker L: Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys. Pathol Oncol Res; 2008 Dec;14(4):423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonal variation of childhood acute lymphoblastic leukaemia is different between girls and boys.
  • The aim of this study was to investigate seasonal trends in the incidence of acute lymphoblastic leukaemia (ALL) around the times of birth and diagnosis in children aged 0-4 years and also to examine gender specific effects.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Seasons
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Sex Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 1999 Apr;53(4):235-8 [10396550.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):549-53 [10507784.001]
  • [Cites] Lancet. 1969 Oct 18;2(7625):826-7 [4186286.001]
  • [Cites] J Community Health. 1982 Spring;7(3):159-70 [7076880.001]
  • [Cites] Br J Cancer. 1997;75(11):1711-3 [9184193.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):406-12 [11161408.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):51-5 [12802809.001]
  • [Cites] J Epidemiol Community Health. 1997 Apr;51(2):151-9 [9196644.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):119-24 [9662261.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):338-44 [11979458.001]
  • [Cites] Pediatr Blood Cancer. 2006 Dec;47(7):944-8 [16421899.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):678 [9484831.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):651-6 [12008082.001]
  • [Cites] Int J Epidemiol. 1992 Apr;21(2):381-6 [1428496.001]
  • [Cites] Lancet. 1989 Feb 18;1(8634):378-9 [2563524.001]
  • [Cites] BMC Public Health. 2003 Mar 24;3:13 [12659651.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Oct;15(4):338-45 [11703681.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):812-7 [9514063.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] JAMA. 2001 Jan 10;285(2):168-9 [11176808.001]
  • [Cites] Orv Hetil. 2003 Sep 21;144(38):1869-71 [14596025.001]
  • (PMID = 18409021.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


68. Pritchard MT, Butow PN, Stevens MM, Duley JA: Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol; 2006 Dec;28(12):816-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review.
  • Significant numbers of children and adolescents with acute lymphoblastic leukemia (ALL) do not adequately adhere to their treatment regimen.
  • [MeSH-major] Patient Compliance. Patient Education as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Secondary Prevention

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164651.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


69. Ficek K, Blamek S, Syguła D, Miszczyk L, Sońta-Jakimczyk D, Tarnawski R: Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy. Acta Neurochir Suppl; 2010;106:195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy.
  • PURPOSE: The aim of the study was to evaluate the late changes seen in Magnetic Resonance Spectroscopy (MRS) of the brain in Acute Lymphoblastic Leukemia (ALL) survivors to assess neurotoxicity following prophylactic treatment with cranial irradiation (CRT) and/or intrathecal (ITMTX) and systemic MTX.
  • CONCLUSION: MRS is a sensitive detector of late metabolic changes after prophylactic treatment for ALL in childhood.
  • [MeSH-major] Brain Injuries. Cranial Irradiation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Case-Control Studies. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Drug Administration Routes. Drug Therapy / methods. Female. Humans. Immunosuppressive Agents / administration & dosage. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Male. Methotrexate / administration & dosage. Tissue Distribution


70. Bongers ME, Francken AB, Rouwé C, Kamps WA, Postma A: Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation. Pediatr Blood Cancer; 2005 Aug;45(2):139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation.
  • BACKGROUND: Impaired linear growth is a well-recognized complication in long-term childhood ALL survivors who received cranial irradiation.
  • METHODS: Reduction of adult height (RAH) was estimated in adult childhood ALL survivors with and without cranial irradiation.
  • RAH was assessed in 79 adult childhood ALL survivors in first complete remission who had received cranial irradiation 25 Gy (Group I, n = 53), 18 Gy (Group II, n = 10) or chemotherapy alone (controls, n = 16).
  • CONCLUSIONS: The deficit between target height and final height highlights the reduction of adult height in the majority of male and female childhood ALL survivors who had received prophylactic cranial irradiation, in particular in those who were diagnosed at a younger age.
  • [MeSH-major] Cranial Irradiation / adverse effects. Growth Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Body Height. Case-Control Studies. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Netherlands / epidemiology. Statistics, Nonparametric


71. Harper JD, Shah SK, Baldwin DD, Moorhead JD: Laparoscopic nephrectomy for pediatric giant hydronephrosis. Urology; 2007 Jul;70(1):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic nephrectomy for pediatric giant hydronephrosis.
  • OBJECTIVES: To describe our experience with pediatric laparoscopic nephrectomy (LN) and laparoscopic nephroureterectomy (LNU) for giant hydronephrosis.
  • METHODS: A retrospective review was conducted of all pediatric patients undergoing a transperitoneal LN or LNU.
  • CONCLUSIONS: Although pediatric LN and LNU for giant hydronephrosis present unique challenges owing to the large renal volume in a small abdominal cavity, these procedures can be safely performed with careful attention to the altered anatomic relationships.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656227.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Singer JS, Ettenger RB, Gore JL, Gritsch HA, Rajfer J, Rosenthal JT, Schulam P: Laparoscopic versus open renal procurement for pediatric recipients of living donor renal transplantation. Am J Transplant; 2005 Oct;5(10):2514-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic versus open renal procurement for pediatric recipients of living donor renal transplantation.
  • Despite reports demonstrating the safety of laparoscopic donor nephrectomy (LDN) for pediatric recipients of renal transplants, recent evidence has challenged using LDN for recipients 5 years of age or younger.
  • We retrospectively reviewed the records of all pediatric recipients of living donor renal transplants from September 2000 through August 2004.
  • Outcomes of interest included operative complications, postoperative renal function, the incidence of delayed graft function or episodes of acute rejection and long-term graft function.
  • Rates of delayed graft function and acute rejection did not differ between groups.
  • At our center, pediatric LDN recipients have graft outcomes comparable to those of ODN recipients.
  • At experienced centers, we recommend continued use of LDN for pediatric recipients of all ages.
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Creatinine / blood. Creatinine / urine. Female. Graft Rejection. Graft Survival. Humans. Kidney / pathology. Living Donors. Male. Nephrectomy / methods. Renal Artery. Retrospective Studies. Time Factors. Tissue and Organ Harvesting / methods. Tissue and Organ Procurement. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162202.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


73. Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH: Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer; 2005 Jan 15;103(2):368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
  • BACKGROUND: The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy.
  • CONCLUSIONS: Despite acceptable long-term second EFS rates for certain subgroups, overall bone marrow recurrence after intensified first-line therapy for childhood ALL signals a poor outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / epidemiology. Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Probability. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Distribution. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15599932.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


74. Mantadakis E, Cole PD, Kamen BA: High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy; 2005 May;25(5):748-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?
  • High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Folic Acid Antagonists / administration & dosage. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Animals. Child. Clinical Trials as Topic. Drug Administration Schedule. Drug Therapy, Combination. Humans. Infusions, Intravenous. Leucovorin / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899736.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Folic Acid Antagonists; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 58
  •  go-up   go-down


75. Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G: Adiposity in childhood cancer survivors: insights into obesity physiopathology. Arq Bras Endocrinol Metabol; 2009 Mar;53(2):190-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adiposity in childhood cancer survivors: insights into obesity physiopathology.
  • As childhood cancer treatment has become more effective, survival rates have improved, and a number of complications have been described while many of these patients reach adulthood.
  • Currently, studies concerning overweight have focused on acute lymphocytic leukemia and brain tumors, since they are at risk for hypothalamic-pituitary axis damage secondary to cancer therapies (cranial irradiation, chemotherapy, and brain surgery) or to primary tumor location.
  • [MeSH-major] Adipose Tissue / physiopathology. Adiposity / physiology. Brain Neoplasms / therapy. Leukemia, Lymphoid / therapy. Obesity / physiopathology
  • [MeSH-minor] Adipogenesis. Child. Humans. Neoplasms / complications. Neoplasms / therapy. PPAR gamma / physiology. Survivors


76. Martin FT, O'Sullivan JB, Regan PJ, McCann J, Kelly JL: Hydrocolloid dressing in pediatric burns may decrease operative intervention rates. J Pediatr Surg; 2010 Mar;45(3):600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrocolloid dressing in pediatric burns may decrease operative intervention rates.
  • INTRODUCTION: Partial-thickness scalds are the most common pediatric burn injury, and primary management consists of wound dressings to optimize the environment for reepithelialization.
  • AIM: The aim of the study was to retrospectively analyze pediatric burns in a single tertiary referral center over a 10-year period comparing the impact of Jelonet and DuoDERM dressings relative to operative intervention rates.
  • METHODS: All pediatric burns admitted between 1997 and 2007 were identified using the Hospital Inpatient Enquiry system.
  • Acute, partial-thickness burns in patients younger than 15 years were analyzed according to dressing type applied (Jelonet or DuoDERM).
  • RESULTS: Two hundred forty-eight pediatric burns were analyzed between 1997 and 2007.
  • CONCLUSION: Observational evidence suggests that DuoDERM leads to less operative intervention and should be preferentially used in pediatric burns.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Injury Severity Score. Length of Stay. Male. Pain Measurement. Probability. Retrospective Studies. Risk Assessment. Treatment Outcome. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Burns.
  • Hazardous Substances Data Bank. PETROLATUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223327.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / jelonet; 8009-03-8 / Petrolatum
  •  go-up   go-down


77. Nilsson B, Andersson A, Johansson M, Fioretos T: Cross-platform classification in microarray-based leukemia diagnostics. Haematologica; 2006 Jun;91(6):821-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-platform classification in microarray-based leukemia diagnostics.
  • As proof-of-principle, we performed cross-platform classification of acute myeloid leukemia and childhood acute lymphoblastic leukemia using expression data from four different facilities.
  • [MeSH-major] Leukemia / classification. Leukemia / genetics. Oligonucleotide Array Sequence Analysis / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769585.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


78. Weinberg ST, Kaiser AB, Waitman LR, Webb T: Experience with ConsultWiz--the simultaneous electronic notification, documentation, and tracking of inpatient consult requests. AMIA Annu Symp Proc; 2006;:1139
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Piloted in the Dept of Medicine in Spring, 2005, ConsultWiz was expanded to include all remaining adult services in July, 2005 and all pediatric consult services in October, 2005.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Healthc Qual. 2003 Jan-Feb;25(1):27-35 [12879628.001]
  • (PMID = 17238758.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1839338
  •  go-up   go-down


79. Irving JA, Minto L, Bailey S, Hall AG: Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course. Cancer Res; 2005 Nov 1;65(21):9712-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course.
  • Glucocorticoids are pivotal in the treatment of children with acute lymphoblastic leukemia (ALL) and have significant antileukemic effects in the majority of children.
  • There was no evidence of a remaining wild-type allele.
  • [MeSH-major] Loss of Heterozygosity. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Glucocorticoid / genetics
  • [MeSH-minor] Alleles. Bone Marrow / pathology. Cell Line, Tumor. Child. Child, Preschool. Cohort Studies. Exons. Gene Deletion. Humans. Microsatellite Repeats / genetics. Prednisolone / therapeutic use. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266991.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


80. Goyal S, Yue NJ, Millevoi R, Kagan E, Haffty B, Narra V: Improvement in dose homogeneity with electronic tissue compensation over IMRT and conventional RT in whole brain radiotherapy. Radiother Oncol; 2008 Aug;88(2):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Ten patients (6 adult, 4 pediatric) who were treated at our institution were selected for this study.
  • At our institution, ECOMP is being used in all pediatric patients or select adult patients with a long life expectancy requiring cranial radiotherapy.
  • [MeSH-minor] Adult. Child. Humans. Radiation Dosage. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362037.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


81. Wong DI, Dockerty JD: Birth characteristics and the risk of childhood leukaemias and lymphomas in New Zealand: a case-control study. BMC Blood Disord; 2006;6:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birth characteristics and the risk of childhood leukaemias and lymphomas in New Zealand: a case-control study.
  • BACKGROUND: Some studies have found that lower parity and higher or lower social class (depending on the study) are associated with increased risks of childhood acute lymphoblastic leukaemia (ALL).
  • An earlier New Zealand study found a protective effect of parental marriage on the risk of childhood ALL, and studies elsewhere have reported increased risks in relation to older parental ages.
  • This study aimed to assess whether lower parity, lower social class, unmarried status and older parental ages increase the risk of childhood ALL (primarily).
  • These variables were also assessed in relation to the risks of childhood acute non-lymphoblastic leukaemia, non-Hodgkin's lymphomas and Hodgkin's disease.
  • RESULTS: There were no statistically significant associations overall between childhood ALL and parity of the mother, social class, unmarried maternal status, increasing parental ages (continuous analysis), or urban status.
  • We also found no statistically significant associations between the risks of childhood acute non-lymphoblastic leukaemia, non-Hodgkin lymphomas, or Hodgkin's disease and the variables studied.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 1999 Mar;53(3):154-8 [10396492.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):977-81 [9378561.001]
  • [Cites] Int J Epidemiol. 1999 Aug;28(4):631-9 [10480689.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1117-21 [10737396.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1522-8 [10995808.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] Cancer Causes Control. 2002 Feb;13(1):15-25 [11899114.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):603-13 [11914187.001]
  • [Cites] Hematol Oncol. 2004 Mar;22(1):11-26 [15152367.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1057-64 [15184264.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1236-43 [15247136.001]
  • [Cites] Scand J Public Health. 2004;32(4):279-86 [15370768.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1075-83 [16184473.001]
  • [Cites] Int J Epidemiol. 2006 Apr;35(2):370-84 [16308412.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):583-98 [16690516.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1189-201 [5329907.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):433-5 [7141739.001]
  • [Cites] Lancet. 1994 Oct 8;344(8928):971-2 [7934425.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1141-7 [8624278.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • (PMID = 16972984.001).
  • [ISSN] 1471-2326
  • [Journal-full-title] BMC blood disorders
  • [ISO-abbreviation] BMC Blood Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1592292
  •  go-up   go-down


82. Berbel Tornero O, Ortega García JA, Ferrís i Tortajada J, García Castell J, Donat i Colomer J, Soldin OP, Fuster Soler JL: [Neonatal tumours and congenital malformations]. An Pediatr (Barc); 2008 Jun;68(6):589-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The association between pediatric cancer and congenital abnormalities is well known but, there is no exclusive data on the neonatal period and the underlying etiopathogenic mechanisms are unknown.
  • RESULTS: 72 neonatal tumours were identified (2.8% of all pediatric cancers diagnosed in our hospital) and in 15 cases (20.8%) there was some associated malformation, disease or syndrome.
  • f) acute leukaemia in one patient with Down syndrome and congenital heart disease;.
  • The publications included the tumours diagnosed in different pediatric periods and without unified criteria to classify the congenital abnormalities.
  • CONCLUSIONS: Neonatal tumours are more often associated to congenital abnormalities than other pediatric cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Nov;78(9):1244-9 [9820188.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1674-9 [8082067.001]
  • [Cites] Med Pediatr Oncol. 1994;22(5):309-17 [8127254.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):357-63 [8347491.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):639-44 [8470665.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):629-38 [8470664.001]
  • [Cites] In Vivo. 1990 Sep-Oct;4(5):327-35 [2133106.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):1025-8 [2069840.001]
  • [Cites] Arch Dis Child. 1987 Jan;62(1):19-23 [3813632.001]
  • [Cites] Cancer Detect Prev. 1986;9(1-2):1-7 [3731185.001]
  • [Cites] Pediatr Pathol. 1985;3(2-4):165-216 [3879355.001]
  • [Cites] Cancer. 2005 May 1;103(9):1939-48 [15770693.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):74-84 [15264275.001]
  • [Cites] Pediatr Surg Int. 2003 Sep;19(7):509-19 [14523568.001]
  • [Cites] Pediatr Surg Int. 2002 Sep;18(5-6):306-9 [12415344.001]
  • [Cites] Curr Oncol Rep. 2000 May;2(3):234-41 [11122848.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):255-67 [16197716.001]
  • (PMID = 18559198.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR020359
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Other-IDs] NLM/ NIHMS459185; NLM/ PMC3635533
  •  go-up   go-down


83. Martin BT, Williamson BD, Edwards N, Teng AY: Parental symptom report and periodic limb movements of sleep in children. J Clin Sleep Med; 2008 Feb 15;4(1):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At their initial sleep clinic visit, parents had been asked whether their child was restless or moved their legs excessively during sleep.
  • Their response to these questions was compared to the child's PLMS index (number of periodic limb movements per hour) during a full PSG.
  • Asking parents about whether their child kicks their legs excessively in sleep had sensitivity 50%, specificity 51%, positive predictive value (PPV) 10%, negative predictive value (NPV) 90% and positive likelihood ratio (LR+) 1.02 when compared to objective analysis.
  • Asking parents about whether their child is restless in sleep had sensitivity 70%, specificity 26%, PPV 9%, NPV 89% and LR+ 0.95.
  • CONCLUSIONS: Asking parents about their child's symptoms is not an accurate predictor of raised PLMS index.
  • We recommend that leg electromyography be used in all pediatric sleep studies to record PLMS.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Infant. Male. New South Wales. Parents. Referral and Consultation / statistics & numerical data. Reproducibility of Results. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 1995;245(1):8-10 [7786913.001]
  • [Cites] Neuropsychopharmacology. 1996 Jun;14(6):437-42 [8726754.001]
  • [Cites] Mov Disord. 1997 Jan;12(1):61-5 [8990055.001]
  • [Cites] J Child Neurol. 1998 Dec;13(12):588-94 [9881529.001]
  • [Cites] Neurology. 1999 Mar 23;52(5):932-7 [10102408.001]
  • [Cites] Sleep. 1999 May 1;22(3):297-300 [10341379.001]
  • [Cites] Dev Med Child Neurol. 2004 Nov;46(11):765-70 [15540638.001]
  • [Cites] Ann Neurol. 2004 Dec;56(6):803-7 [15505786.001]
  • [Cites] Pediatr Pulmonol. 2005 Jul;40(1):22-30 [15858805.001]
  • [Cites] Sleep Med. 2005 Jul;6(4):325-32 [15978516.001]
  • [Cites] Sleep. 2005 Aug 1;28(8):1007-13 [16218085.001]
  • [Cites] Sleep Med. 2005 Nov;6(6):507-13 [16271695.001]
  • [Cites] Paediatr Respir Rev. 2006;7 Suppl 1:S55-7 [16798596.001]
  • [Cites] Sleep. 2006 Sep;29(9):1183-7 [17040005.001]
  • [Cites] Mov Disord. 1999 Nov;14(6):1000-7 [10584676.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):502-4 [10668725.001]
  • [Cites] Sleep. 2001 May 1;24(3):313-20 [11322714.001]
  • [Cites] Psychiatry Clin Neurosci. 2001 Jun;55(3):305-10 [11422885.001]
  • [Cites] Sleep. 2002 Mar 15;25(2):213-8 [11902431.001]
  • [Cites] J Psychosom Res. 2002 Jul;53(1):547-54 [12127170.001]
  • [Cites] J Sleep Res. 2003 Mar;12(1):73-81 [12603789.001]
  • [Cites] Sleep. 2003 Jun 15;26(4):480-3 [12841376.001]
  • [Cites] Sleep. 2003 Sep15;26(6):735-8 [14572128.001]
  • [Cites] Sleep Med. 2003 Mar;4(2):101-19 [14592341.001]
  • [Cites] Sleep. 2004 Mar 15;27(2):313-5 [15124728.001]
  • [Cites] Ann Neurol. 1980 Oct;8(4):416-21 [7436384.001]
  • [Cites] Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1235-9 [1443877.001]
  • (PMID = 18350964.001).
  • [ISSN] 1550-9389
  • [Journal-full-title] Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
  • [ISO-abbreviation] J Clin Sleep Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2276827
  •  go-up   go-down


84. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M: Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis; 2005 Mar;11(3):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infliximab efficacy in pediatric ulcerative colitis.
  • METHODS: All pediatric patients with ulcerative colitis who received infliximab between July 2001 and November 2003 at the Johns Hopkins Children's Center were identified.
  • RESULTS: Twelve pediatric patients with ulcerative colitis received infliximab for treatment of fulminant colitis (3 patients), acute exacerbation of colitis (3), steroid-dependent colitis (5), and steroid-refractory colitis (1).
  • CONCLUSION: Infliximab should be considered in the treatment of children with symptoms of acute moderate to severe ulcerative colitis.
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Child. Child, Preschool. Colectomy. Female. Humans. Infliximab. Male. Retrospective Studies. Severity of Illness Index. Treatment Outcome. Tumor Necrosis Factor-alpha


85. Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY, Ahn HS: Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood; 2007 Jan 15;109(2):471-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia.
  • However, little is known about the clinical relevance of Livin expression in childhood acute lymphoblastic leukemia (ALL).
  • In this study, the expression of Livin was analyzed in 222 patients with childhood ALL using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate a possible association with the clinical features at diagnosis and treatment outcomes.
  • Multivariate analysis for relapse-free survival demonstrated that Livin expression was an independent favorable prognostic factor in childhood ALL (P=.049).
  • This study suggests that Livin expression is a novel prognostic marker in childhood ALL and thus needs to be incorporated into the patient stratification and treatment protocols.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Biomarkers, Tumor / genetics. Gene Expression Profiling. Gene Expression Regulation, Leukemic / genetics. Inhibitor of Apoptosis Proteins / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Proliferation / drug effects. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Methylprednisolone / pharmacology. Molecular Sequence Data. Predictive Value of Tests. Prognosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990595.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ NM139317
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC7 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


86. O'Connor KC, Lopez-Amaya C, Gagne D, Lovato L, Moore-Odom NH, Kennedy J, Krupp L, Tenembaum S, Ness J, Belman A, Boyko A, Bykova O, Mah JK, Stoian CA, Waubant E, Kremenchutzky M, Ruggieri M, Bardini MR, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman MS, Iivanainen M, Bhan V, Dilenge M, Hancock MA, Gano D, Fattahie R, Kopel L, Fournier AE, Moscarello M, Banwell B, Bar-Or A: Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol; 2010 Jun;223(1-2):92-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis.
  • Anti-myelin basic protein (MBP) antibodies in pediatric-onset MS and controls were characterized.
  • Paired CSF and serum were obtained from 25 children with MS at time of their initial episode of acute demyelinating syndrome (ADS).
  • While the prevalence and titers of serum anti-MBP antibodies against both immature and mature forms of MBP were similar in children with MS and in controls, binding characteristics and formal Surface Plasmon Resonance (SPR) studies indicated surprisingly high binding affinities of all pediatric anti-MBP antibodies.
  • Serum levels of anti-MBP antibodies correlated significantly with their CSF levels, and their presence in children with MS was associated with significantly increased risk of an acute disseminated encephalomyelitis-like initial clinical presentation.
  • While antibodies to both immature and mature forms of MBP can be present as part of the normal pediatric humoral repertoire, these anti-myelin antibodies are of surprisingly high affinity, can access the CNS during inflammation, and have the capacity to modulate disease expression.
  • [MeSH-minor] Acute Disease. Adolescent. Biomarkers / blood. Biomarkers / cerebrospinal fluid. Child. Child, Preschool. Female. Humans. Infant. Male. Myelin Basic Protein. Risk Factors. Syndrome. Young Adult

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20381173.001).
  • [ISSN] 1872-8421
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / MBP protein, human; 0 / Myelin Basic Protein; 0 / Nerve Tissue Proteins; 0 / Transcription Factors
  •  go-up   go-down


87. Julia AR, Basílico H, Magaldi G, Demirdjian G: [Transfusional requirements for escharectomy in burned children]. Arch Argent Pediatr; 2010 Feb;108(1):55-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: All pediatric patients with acute burns excised at the Burn Unit of the Hospital Garrahan during one year were included.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Longitudinal Studies. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Burns.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204240.001).
  • [ISSN] 1668-3501
  • [Journal-full-title] Archivos argentinos de pediatría
  • [ISO-abbreviation] Arch Argent Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


88. Cooley LD, Mascarello JT, Hirsch B, Jacky PB, Rao PN, Saxe D, Rao KW, Working Group of the American College of Medical Genetics (ACMG) Laboratory Quality Assurance Committee: Section E6.5 of the ACMG technical standards and guidelines: chromosome studies for solid tumor abnormalities. Genet Med; 2009 Dec;11(12):890-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is recommended that all pediatric solid tumors be studied by cytogenetic analysis when feasible due to the clinical and therapeutic implications of the genetic abnormalities.
  • [MeSH-minor] Adult. Child. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence / methods. In Situ Hybridization, Fluorescence / standards. Karyotyping. Prognosis

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Laboratory Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010366.001).
  • [ISSN] 1530-0366
  • [Journal-full-title] Genetics in medicine : official journal of the American College of Medical Genetics
  • [ISO-abbreviation] Genet. Med.
  • [Language] eng
  • [Publication-type] Guideline; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Regan SM, Rink RC, Kaefer M, Meldrum KD, Misseri R, Cain MP: The role of routine postoperative stentograms in the pediatric patient undergoing excisional tapered ureteral reimplantation. J Pediatr Urol; 2009 Dec;5(6):472-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of routine postoperative stentograms in the pediatric patient undergoing excisional tapered ureteral reimplantation.
  • OBJECTIVE: To determine the usefulness of routine stentograms in postoperative management of pediatric patients undergoing excisional tapered ureteral reimplantation.
  • MATERIALS AND METHODS: A retrospective review of all pediatric patients undergoing excisional tapered ureteral reimplantation from March 2003 to March 2008 at one center was performed.
  • RESULTS: Of the 17 pediatric patients with postoperative stentograms, 10 (59%) had no contrast observed in the bladder.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Fluoroscopy. Humans. Infant. Postoperative Care. Retrospective Studies. Stents. Urinary Diversion

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362519.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


90. Englesbe MJ, Lynch RJ, Heidt DG, Thomas SE, Brooks M, Dubay DA, Pelletier SJ, Magee JC: Early urologic complications after pediatric renal transplant: a single-center experience. Transplantation; 2008 Dec 15;86(11):1560-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early urologic complications after pediatric renal transplant: a single-center experience.
  • BACKGROUND: Urologic complications cause substantial morbidity in the pediatric population after renal transplantation, but their impact on graft survival and transplant costs is poorly understood.
  • In this retrospective review, we evaluated the records of all pediatric renal transplant recipients at our center from 1995 to 2004.
  • Sex, ischemia time, race, previous transplant, donor type, nephrectomy technique, and stent use did not affect the incidence of urologic complications.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Graft Survival. Humans. Infant. Infant, Newborn. Male. Reoperation. Retrospective Studies. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077890.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. de Benedictis FM, de Benedictis D, Canonica GW: New oral H1 antihistamines in children: facts and unmeet needs. Allergy; 2008 Oct;63(10):1395-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the past, the pharmacokinetics and pharmacodynamics of H1 antihistamines have not been optimally investigated in the pediatric population, especially in infants and young children.
  • In the pediatric population, clinical studies with new-generation antihistamines are still limited in number and, with rare exceptions, of brief duration.
  • CONCLUSIONS: Properly designed, long-term trials with new-generation H1 antihistamines need to be performed in single age groups, in order to better define the effects of these drugs in all pediatric population.
  • [MeSH-minor] Administration, Oral. Child. Humans. Hypersensitivity / drug therapy. Hypersensitivity / metabolism. Infant. Receptors, Histamine H1 / genetics. Receptors, Histamine H1 / metabolism

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782118.001).
  • [ISSN] 1398-9995
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Histamine H1 Antagonists, Non-Sedating; 0 / Receptors, Histamine H1
  • [Number-of-references] 65
  •  go-up   go-down


92. de Ridder L, van Lingen AV, Taminiau JA, Benninga MA: Rectal bleeding in children: endoscopic evaluation revisited. Eur J Gastroenterol Hepatol; 2007 Apr;19(4):317-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Rectal bleeding is an alarming event both for the child and parents.
  • STUDY DESIGN: All pediatric patients undergoing colonoscopy because of prolonged rectal bleeding over an 8-year period at the Emma Children's Hospital/Academic Medical Centre were reviewed.
  • RESULTS: A total of 147 colonoscopies were performed in 137 pediatric patients (63 boys) because of prolonged rectal bleeding.
  • [MeSH-minor] Abdominal Pain / etiology. Abdominal Pain / pathology. Adolescent. Child. Child, Preschool. Colonoscopy. Cross-Sectional Studies. Diarrhea / etiology. Diarrhea / pathology. Duodenoscopy. Esophagoscopy. Female. Gastroscopy. Humans. Infant. Inflammatory Bowel Diseases / complications. Inflammatory Bowel Diseases / pathology. Intestinal Polyps / complications. Intestinal Polyps / pathology. Male. Rectum. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353696.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Morsi H, Yong KL, Jewell AP: Preferential survival of acute lymphoblastic leukemia cells at 33 degrees C is associated with up-regulation of bcl-2. Leuk Lymphoma; 2006 Jun;47(6):1117-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential survival of acute lymphoblastic leukemia cells at 33 degrees C is associated with up-regulation of bcl-2.
  • An important feature of childhood acute lymphoblastic leukemia (ALL) is the risk of testicular relapse in affected males, which may occur months or years after induction of remission.
  • Acute myeloid leukemia cell lines incubated at 33 degrees C also showed increased survival and resistance to chemotherapeutic agents, but did not demonstrate upregulation of bcl-2.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840204.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


94. Metzler M, Mann G, Monschein U, Lodzinski M, Gall C, Flohr T, Viehmann S, Langer T, Schrappe M, Gadner H, Haas OA, Panzer-Grümayer ER: Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene. Haematologica; 2006 May;91(5):683-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene.
  • Quantification of minimal residual disease (MRD) based on clonotypic immunoglobulin/ T-cell receptor (Ig/TCR) gene rearrangements is widely used as an independent prognostic parameter in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 21 / genetics. Core Binding Factor Alpha 2 Subunit / analysis. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Oncogene Proteins, Fusion / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic / genetics. Child. Child, Preschool. Clone Cells / ultrastructure. DNA, Neoplasm / genetics. Disease-Free Survival. Female. Humans. Infant. Male. Molecular Sequence Data. Neoplasm, Residual. Preleukemia / genetics. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627248.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AJ888033/ AJ888035/ AJ888036/ AJ888037/ AJ888038/ AJ888040/ AJ888041/ DQ100455/ DQ100456/ DQ100457/ DQ100458/ DQ100459
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA, Neoplasm; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


95. Egan K, Kusao I, Troelstrup D, Agsalda M, Shiramizu B: Mitochondrial DNA in residual leukemia cells in cerebrospinal fluid in children with acute lymphoblastic leukemia. J Clin Med Res; 2010 Oct 11;2(5):225-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial DNA in residual leukemia cells in cerebrospinal fluid in children with acute lymphoblastic leukemia.
  • This feasibility study was designed to assess the ability to measure mitochondrial DNA (mtDNA) in cerebrospinal fluid (CSF) cells that contributed to minimal disease/persistent or residual disease (MD/PRD) from children with acute lymphoblastic leukemia (ALL).
  • Increase of mtDNA copy numbers in MD/PRD childhood ALL cells and its significance as a mechanism for recurrence requires further investigation.
  • KEYWORDS: Minimal residual disease; Acute lymphoblastic leukemia; Central nervous system; Cerebrospinal fluid; Mitochondria.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21331151.001).
  • [ISSN] 1918-3011
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR011091; United States / NCRR NIH HHS / RR / P20 RR011091-15; United States / NCI NIH HHS / CA / R21 CA121955; United States / NCI NIH HHS / CA / R21 CA121955-02; United States / NIMHD NIH HHS / MD / U54 MD007584
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ NIHMS237217; NLM/ PMC3039488
  •  go-up   go-down


96. Lönnerholm G, Nordgren A, Frost BM, Jonsson OG, Kanerva J, Nygaard R, Schmiegelow K, Larsson R, Forestier E: Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids. Leukemia; 2009 Jan;23(1):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids.
  • [MeSH-major] Chromosome Aberrations. Drug Resistance, Neoplasm / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / pharmacology. Asparaginase / pharmacology. Child. Child, Preschool. Chromosomes, Human, Pair 20. Chromosomes, Human, Pair 9. Cytarabine / pharmacology. Humans. Infant

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615108.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 04079A1RDZ / Cytarabine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


97. Sagan ML, Datta JC, Olney BW, Lansford TJ, McIff TE: Residual deformity after treatment of pediatric femur fractures with flexible titanium nails. J Pediatr Orthop; 2010 Oct-Nov;30(7):638-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual deformity after treatment of pediatric femur fractures with flexible titanium nails.
  • This article reports on a clinical evaluation of angulation after treating pediatric femur fractures with FTNs.
  • METHODS: All pediatric femoral shaft fractures treated with FTNs over a 4-year period were reviewed.
  • [MeSH-minor] Adolescent. Biomechanical Phenomena. Bone Nails. Child. Child, Preschool. Fracture Healing. Humans. Retrospective Studies. Titanium. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20864845.001).
  • [ISSN] 1539-2570
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] D1JT611TNE / Titanium
  •  go-up   go-down


98. Wilson PE, Oleszek JL, Clayton GH: Pediatric spinal cord tumors and masses. J Spinal Cord Med; 2007;30 Suppl 1:S15-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric spinal cord tumors and masses.
  • BACKGROUND/OBJECTIVE: Spinal cord tumors are a relatively rare diagnosis, accounting for 1% to 10% of all pediatric central nervous system tumors.
  • RESULTS: Neurodevelopmental tumors (dermoid tumors, epidermoid tumors, and teratomas) were the most common tumor type (31%), followed by astrocytomas (29%) and neuroblastomas (14%).
  • Mean age at diagnosis was 6.6 years (SD = 5.5 y) and did not vary significantly by tumor type except for children with neuroblastoma (mean = 0.4 y, SD = 0.5 y).
  • More boys (57%) were identified in the series than girls (43%); however, there was no association between tumor type and sex.
  • CONCLUSIONS: This study corroborates other studies indicating that intramedullary tumors are the predominant form of pediatric spinal cord tumor.
  • The disparity may be the result of this institution acting as a regional referral center, thus increasing the number of this type of patient.
  • Although, in general, spinal cord tumors are relatively rare, this preliminary study supports the need to further evaluate associations between tumor type, presenting symptoms, treatment, and functional outcome in children with spinal cord tumors.
  • [MeSH-minor] Astrocytoma. Child. Child, Preschool. Female. Humans. Infant. Male. Meningioma. Neurilemmoma. Neuroblastoma. Retrospective Studies. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:550-89 [10800501.001]
  • [Cites] Neurosurg Focus. 2001;10(1):e3 [16749755.001]
  • [Cites] Pediatr Neurosurg. 2001 Sep;35(3):120-7 [11641619.001]
  • [Cites] Childs Nerv Syst. 2003 Sep;19(9):641-9 [12908118.001]
  • [Cites] Pediatr Neurosurg. 2004 Jan-Feb;40(1):16-22 [15007224.001]
  • [Cites] Semin Roentgenol. 2004 Jul;39(3):347-60 [15372749.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] J Neurosurg. 1967 Feb;26(2):276-82 [6019134.001]
  • [Cites] Clin Neurosurg. 1978;25:512-39 [568531.001]
  • [Cites] J Comput Assist Tomogr. 1981 Apr;5(2):274 [7217456.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1869-86 [2992750.001]
  • [Cites] Childs Nerv Syst. 1987;3(2):89-92 [3040249.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):523-32 [2319309.001]
  • [Cites] Neurosurg Clin N Am. 1992 Oct;3(4):931-45 [1392585.001]
  • [Cites] J Child Neurol. 1992 Oct;7(4):360-3 [1469242.001]
  • [Cites] Neurosurgery. 1994 Jul;35(1):69-74; discussion 74-6 [7936155.001]
  • [Cites] Int J Epidemiol. 1994 Jun;23(3):458-64 [7960369.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Feb 15;22(4):442-51 [9055374.001]
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):293-5 [9251736.001]
  • [Cites] Childs Nerv Syst. 1999 Jan;15(1):17-28 [10066016.001]
  • [Cites] Childs Nerv Syst. 1999 Sep;15(9):436-8 [10501998.001]
  • [Cites] Spinal Cord. 2005 Jan;43(1):34-41 [15326473.001]
  • [Cites] Neurosurg Focus. 2005 Feb 15;18(2):ECP1 [15715454.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):22-8 [15886509.001]
  • [Cites] Neurosurg Clin N Am. 2006 Jan;17(1):51-61 [16448908.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1129-43; discussion 1129-43 [16723892.001]
  • [Cites] J Neurooncol. 2000 May;47(3):225-30 [11016739.001]
  • (PMID = 17874681.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2031985
  •  go-up   go-down


99. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia; 2010 Feb;24(2):355-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.
  • From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies.
  • Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7+/-1.2%, 68.1+/-1.4% and 73.2+/-2.1%, respectively.
  • Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20016527.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / CA 29139; United States / NCI NIH HHS / CA / U10 CA030969-22; United States / NCI NIH HHS / CA / U10 CA029139-22; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA 30969; United States / NCI NIH HHS / CA / U10 CA029139; United States / NCI NIH HHS / CA / U10 CA098543-07; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA030969; United States / NCI NIH HHS / CA / U10 CA098413-07; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS158683; NLM/ PMC4300959
  •  go-up   go-down


100. Ociepa T, Maloney E, Kamieńska E, Wysocki M, Kurylak A, Matysiak M, Urasiński T, Urasińska E, Domagała W: Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia. Pol J Pathol; 2010;61(4):199-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.
  • Ineffective apoptosis is one of main causes of a treatment failure in childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Leukocytes, Mononuclear / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisone / therapeutic use. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Female. Humans. Infant. Male. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21290342.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; VB0R961HZT / Prednisone
  •  go-up   go-down






Advertisement